PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 1
A PHASE 1B, 12-WEEK, OPEN-LABEL STUDY TO ASSESS THE SAFETY, 
TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS
FOLLOWING REPEATED SUBCUTANEOUS ADMINISTRATIONS OF 
PF-06946860 IN PATIENTS WITH CANCER AND CACHEXIA
Investigational Product Number: PF-06946860
Investigational Product Name: Not Applicable (N/A)
United States (US) Investigational New 
Drug (IND) Number:
European Clinical Trials Database 
(EudraCT) Number:Not Applicable (N/A)
Protocol Number: C3651009
Phase: 1b
Short Title: Study to Assess Safety, Tolerability, Pharmacokinetics and 
Pharmacodynamics following Repeated Subcutaneous Administrations of PF-06946860 in Patients with Cancer and Cachexia
This document and accompanying materials contain confidential information belonging to Pfizer.  Except as 
otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this information in 
confidence and not copy or disclose it to others (except where required by applicable law) or use it for 
unauthorized purposes.  In the event of any actual or suspected breach of this obligation, Pfizer must be 
promptly notified.CCI
PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 2Protocol Amendment Summary of Changes Table
Document History
Document Version Date Summary of Changes and Rationale
Amendment 1 08 February 2021 The rationale for this amendment overall is 
to streamline participant workflow, minimize participant testing burden, and include more cancer populations. The rationale for other changes are based upon completion of the C3651001 and C3651002 CSRs, incorporate PACL items, incorporate protocol template items and correction of spelling errors.  The updates are as follows:
Addition of pancreatic and colorectal 
cancer throughout the protocol.
Removal of DXA scan as a study 
procedure noted throughout protocol.
Removal of PROs  
from Cohort 2 noted throughout protocol.
Added flexibility for CT scan timing noted 
in SoA.
Updates from current IB (Section 2.2) and 
added 6-month nonclinical monkey data to Section 2.2.3.
Schema-updated based upon changes to the 
procedures and SoA.
SoA: 
•Added a second screening GDF-15 
samples to allow analysis using the internal Pfizer assay(s). The additional sample will serve as a baseline prior to standard-of-care anti-tumor therapy for patients who enter the study at the second cycle of standard of careCCI
PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 3anti-tumor therapy.
•Added an immunogenicity sample at 
Week 15 since this is the end of the dosing interval after the last dose of PF-06946860.
•Changed V13 from an at-home visit to 
a clinic visit with additional procedures noted in SOA and increased visit window from ±1 to ±3 days.
•Added safety labs and pregnancy test to
V14 noted in SOA.
•Added pregnancy test to V15 noted in 
SoA.
•  
 
Section 2.2.2:
•Statement regarding the low risk of 
developing ADA was removed as ADA data from C3651001 and C3651002 are presented in Section 2.2.4.
Section 2.2.4: 
•Updated based on emerging data from 
C3651001 and C3651002.
Section 3: 
•PK endpoint has been updated to 
trough concentrations (C
trough) of 
PF-06946860 as this is a PK parameter of interest. 
Section 4.3: 
•Updated based on updated PK/PD 
modeling and simulation results. Safety CCI
PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDENTIAL
Page 4margin updated based on 6- month 
monkey toxicolog ydata. 
Clarified i f a different dosing frequency  
is selected for Cohort 2, this will be 
implemented via a proto col 
amendment .
Section 5: 
Inclusion 
Criterion # 3 modified for 
additional cancer t ypes.
Inclusion Criterion # 6 modified for 
allowable therapie s.
Inclusion Criterion # 8- minor 
corrections.
Exclusion Criterion #1- clarification of 
excluded cancer t ypes.
Exclusion Criterion
#2-updated for 
clarity .
Exclusion Criterion # 3 -added for 
clarification of radiation therap y.
Exclusion Criterion # 13 -removed
secon d bullet.
Exclusion Criterion # 1 5-removed.
Added the following sections to align with 
the updated protocol template: 
Sections 8.3.6, Section 8.3.7, 8.3.8 and 
8.3.8.1.
Section 8.0 :
Blood volume increased based on
additional samples forsafety,bioba nk 
and internal assay .

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDENTIAL
Page 5Section 8.4: 
Overdose updated based on upda ted 
PK/PD simulation results and NOAEL
from 6- month monkey  toxicology  
study . Definition of overdose for this 
study  was redefined based on 
operational considerations. 
Sections 8.5, 8.6 and 8.9:
U
pdated per updated protocol te mplate 
text. 
Section 8.6 upda ted per SOA . 
Section 8.8.1:
Updated Prep B2 and Prep 1.5 sample 
descripti onsfor clarity .
Appendix 10.4: 
Updated contraception requirements 
per emerging PK data from C3651001
.
Updated pr otocol to include PACL  items:
Apre-dose PK sample will also be 
collected on Day  1 in addition to the 
post-dose PK sample.
Radiation as primary  SOC is not 
permitted (allowed for metas tases for 
palliative care)
Inclusion 
Criterion # 6-Paclitaxel or 
nab-paclitaxel is permitted as an 
allow able th erapy. Therefore, the 
allowable therapies are a platin + 
pemetrexed ± pembrolizumab or a 
platin + nab pacli taxel or paclitaxel
± pembrolizumab as first or second line 
therap y.
Original protocol 27November 2019 Not a pplicable ( N/A)

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDENTIAL
Page 6TABLE OF CONTENTS
LIST OF TABLES ................................ ................................ ................................ ................... 11
1. PROTOCOL  SUMMARY ...................................................................................................12
1.1. Sy nopsis ................................ ................................ ................................ .................. 12
1.2. Schema ....................................................................................................................12
1.3. Schedule of Activities (SoA) ...................................................................................13
2. INTRODUCTION ...............................................................................................................17
2.1. Study  Rationale .......................................................................................................17
2.2. Background .............................................................................................................18
2.2.1. N onclinical Pharma cology ..........................................................................18
2.2.2. Nonclinical Pharmacokinetics and Metabolism
.........................................18
2.2.3. Nonclinical Safet y
......................................................................................19
2.2.4. Clinical Overview .......................................................................................19
2.2.4.1. Summary  of Safety  Data ...........................................................20
2.2.4.2. Summary  of Pharmacokinetics ..................................................20
2.2.4.3. Summary  of Pharmacod ynamics ...............................................20
2.2.4.4. Summary  of Immunogenicit y
....................................................22
2.3. Benefit/Risk Assessment
.........................................................................................22
3. OBJECTI
VES AND EN DPOINTS .....................................................................................22
4. STUDY DESIGN .................................................................................................................24
4.1. Overall Design .........................................................................................................24
4.2. Scientific Rationale for Study  Design .....................................................................25
4.3. Justification for Dose ..............................................................................................27
4.4. End of Study  Definition ..........................................................................................28
5.STUDY POPUL ATION
................................ ................................ ................................ ......29
5.1. I nclusion Criteria .....................................................................................................29
5.2. Exclusion Criteria ....................................................................................................31
5.3. L ifesty le Considerations ..........................................................................................33
5.3.1. Contracep tion..............................................................................................33
5.4. Screen Failures ........................................................................................................33
6. STUDY INTERVENTIO N
................................ ................................ ................................ ..34

PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 76.1. Study Intervention(s) Administered ........................................................................34
6.1.1. Administration ............................................................................................35
6.2. Preparation/Handling/Storage/Accountability ........................................................35
6.2.1. Preparation and Dispensing ........................................................................36
6.3. Measures to Minimize Bias: Randomization and Blinding.....................................36
6.3.1. Allocation to Investigational Product .........................................................36
6.4. Study Intervention Compliance...............................................................................376.5. Concomitant Therapy..............................................................................................376.6. Dose Modification...................................................................................................376.7. Intervention After the End of the Study..................................................................38
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/ WITHDRAWAL...........................................................................38
7.1. Discontinuation of Study Intervention ....................................................................38
7.1.1. Criteria for Discontinuation........................................................................38
7.2. Participant Discontinuation/Withdrawal from the Study........................................387.3. Lost to Follow-up ....................................................................................................39
8. STUDY ASSESSMENTS AND PROCEDURES...............................................................40
8.1. Efficacy Assessments..............................................................................................41
8.1.1. Body Weight...............................................................................................418.1.2. Imaging Assessment ...................................................................................41
8.1.2.1. CT Scan .....................................................................................41
8.1.3. Patient-Reported Outcomes (Cohort 1) ......................................................42
8.1.3.2. Patient-Reported Outcomes Version of the Common 
Terminology Criteria for Adverse Events (PRO-CTCAE
™).............43
8.1.3.3. Patient’s Global Impression of Severity (PGI-S)......................448.1.3.4. Patient’s Global Impression of Change (PGI-C).......................448.1.3.5. PROMIS – Fatigue (version 7a)................................................448.1.3.6. PROMIS – Physical Function (version 8c) ...............................448.1.3.7. Functional Assessment of Anorexia-Cachexia Therapy 
(FAACT) ...........................................................................................45CCI
CCI
PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDENTIAL
Page 88.2. Safet y Assessments .................................................................................................45
8.2.1. Phy sical Examinations ................................................................................46
8.2.2. Eastern Coopera tive Oncology  Group (ECOG) .........................................46
8.2.3. Vital Signs ..................................................................................................46
8.2.4. Electrocardiograms
.....................................................................................46
8.2.5. Clinical Safety  Laboratory  Assessments ....................................................47
8.2.6. Pregn ancy  Testing ......................................................................................48
8.3. Adverse Events and Serious Adverse Even t
s..........................................................48
8.3.1. Time Period and Frequency  for Collecting AE and SAE Information .......48
8.3.1.1. Reporting SAEs to Pfizer Safety ...............................................49
8.3.1.2. Recordi ng Nonserious AEs and SAEs on the CRF ...................49
8.3.2. Method of Detecting AEs and SAEs ..........................................................50
8.3.3. Follow -up of AEs and SAEs .......................................................................50
8.3.4. Regulatory  Reporting Requirements for SAEs ...........................................50
8.3.5. Exposure During Pregnancy  or Breastfeeding, and Occupational 
Exposure ..........................................................................................................51
8.3.5.1. Exposure During Pregnancy ......................................................51
8.3.5.2. Exposure During Breastfeed i
ng ................................................51
8.3.5.3. Occupational Exposure .............................................................51
8.3.6. Cardiovascular and Death Events ...............................................................51
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not 
Qualifying as AEs or SAEs ..............................................................................51
8.3.8.1. Lack of Efficacy ........................................................................52
8.3.9. Medical Device Deficiencies ................................ ................................ ......52
8.3.10. Medication Errors .....................................................................................52
8.4. Treatment of Overdose
............................................................................................53
8.5. Pharmacokinetics ....................................................................................................53
8.6. Pharmacod ynamics of GDF -
15...............................................................................54
8.7. Genetics ...................................................................................................................55
8.7.1. Specified Genetics ......................................................................................55
8.7.2. Banked Biospecimens for Genetics ................................ ............................ 55
8.8. Biomarkers ..............................................................................................................55

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDENTIAL
Page 98.8.1. Banked Biospecimens for Biomarkers .......................................................56
8.9. I mmunogenicit y Assessments .................................................................................56
8.10. Health Economics .................................................................................................57
9. STATI STICAL CONSI DERATIONS
................................................................................57
9.1. Estimands and Statistical Hy potheses .....................................................................57
9.2. Sample Size Determination .....................................................................................57
9.3. Populations for Analy sis.........................................................................................58
9.4. Statistical Analy s
es .................................................................................................58
9.4.1. Efficacy  Anal yses.......................................................................................58
9.4.2. Safet y Anal yses..........................................................................................58
9.4.2.1. E
lectrocardiogram Analy ses......................................................59
9.4.3. Pharmacokinetic Analy ses..........................................................................59
9.4.4. Other Anal yses............................................................................................60
9.4.4.1. Pharmacod ynam ic Anal yses.....................................................60
9.4.4.2. I mmunogenicit y Analy ses.........................................................60
9.5. I nterim Anal yses.....................................................................................................60
9.5.1. Data Monitoring Committee .......................................................................60
10. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS ..........................................................................................................61
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ...............61
10.1.1. Regulatory and Ethical Considerations ....................................................61
10.1.1.1. Reporting of Safety  Issues and Serious Breaches of the 
Protocol or I CH GCP .........................................................................61
10.1.2. Financial Disclosure ................................ ................................ ................. 62
10.1.3. Informed Consent Process ........................................................................62
10.1.4. Data Protection .........................................................................................63
10.1.5. Dissemination of Clinical Study  Data ......................................................63
10.1.6. Data Qualit y Assurance ............................................................................65
10.1.7. Source Documents ....................................................................................66
10.1.8. Study  and Site Closure ..............................................................................66
10.1.9. Publication Policy
.....................................................................................67
10.1.10. Sponsor’s Qualified Medical Personnel ................................ ................. 68

PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 1010.2. Appendix 2: Clinical Laboratory Tests .................................................................69
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting ......................................................................70
10.3.1. Definition of AE .......................................................................................7010.3.2. Definition of SAE.....................................................................................7110.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs.......................7310.3.4. Reporting of SAEs....................................................................................76
10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information ................................................................................................................77
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................7710.4.2. Female Participant Reproductive Inclusion Criteria.................................7710.4.3. Woman of Childbearing Potential (WOCBP) ..........................................7810.4.4. Contraception Methods.............................................................................79
10.5. Appendix 5: Genetics ............................................................................................8210.6. Appendix 6: Liver Safety: Suggested Actions and Follow-up Assessments ........8310.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................85
10.9. Appendix 9: Patient-Reported Outcomes Version of the Common 
Terminology Criteria for Adverse Events PATIENT (PRO-CTCAE™)..................88
10.10. Appendix 10: Patient’s Global Impression of Severity (PGI-S) .........................8910.11. Appendix 11: Patient’s Global Impression of Change (PGI-C)..........................9010.12. Appendix 12: PROMIS – Fatigue (version 7a)...................................................9110.13. Appendix 13: PROMIS – Physical Function (version 8c) ..................................9210.14. Appendix 14: Functional Assessment of Anorexia-Cachexia Therapy 
(FAACT) ...................................................................................................................93
10.16. Appendix 16: ECOG Performance Status...........................................................97
10.17. Appendix 17: RECIST 1.1 Tumor Assessment Criteria RECIST 
(Response Evaluation Criteria In Solid Tumors) version 1.1 Guidelines .................98
10.18. Appendix 18: Modification of Diet in Renal Disease Equation........................10310.19. Appendix 19: Proposed Chronology of Procedures..........................................104
10.20. Appendix 20: Alternative Measures During Public Emergencies.....................107
10.20.1. Eligibility ..............................................................................................107CCI
CCI
PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 1110.20.2. Home Health Visits...............................................................................107
10.20.3. Adverse Events and Serious Adverse Events .......................................107
10.21. Appendix 21: Abbreviations .............................................................................108
11. REFERENCES ................................................................................................................1 12
LIST OF TABLES
 
 
Table 2. Patient Reported Outcomes for Cohort 1..................................................43
Table 3. Protocol-Required Safety Laboratory Assessments .................................69Table 4. Objective Response Status at each Evaluation .......................................102Table 5. Objective Response Status at each Evaluation for Patients with Non 
Target Disease Only ...............................................................................102CCI
PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 121. PROTOCOL SUMMARY 
1.1. Synopsis Not Applicable.
1.2. Schema
The following schema applies to Cohort 1.
CCI
PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDENTIAL
Page 131.3.Schedule of Activ ities(SoA )
The SoA table provides an overvie w of the protocol visits and procedures. Refer t o the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may schedule vis its (unplanned visits) in additio n to those listed in the SoA table, in order to conduct evaluations or 
assessments required to protect the well -being of the participant. 

PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 14Visit Identifier ScreeningaTreatment EOT Follow UpbET
Visit Number v1 v2 v3 v4 v5 v6 v7 v8 v9 v10 v11 v12 v13 v14 v15
Study Week (relative to Day 1) w1 w2 w3 w4 w5 w6 w9 w12 w13 w14 w15 w18 w24
Study Day (relative to Day 1 dosing) -28 to -1 1 8 15 22 29 36 43 64 85 92 99 106 127 169
Visit Window (days) ±1 ±1 ±3 ±1 ±1 ±3 ±3 ±3 ±1 ±1 ±3 ±7 ±7
Clinic Visit X X X X X X X X X X
At-Home VisitcXX XX XX
Informed Consent and Registration X
Review of Eligibility Criteria X X
Medical History and Demography X
Record Prior or Concomitant treatments X X X X X X X X X X
Monitor Serious/nonserious AEsdX X→→ X→→ X X X→→ X X X X
Review contraception use X X X X X X X X X X
Physical ExaminationeX X X X X X X X X X
Weight (+ Height at Screening only) X X X X X X X X X X
Supine vital signsfX X X X X X X X X X
Supine standard 12-Lead ECGgX X X X X X X X X X
CT scan Xh,iXh,iXh,i,jXj
ECOG Performance X X X X X X
Randomization X
Administration of IP (PF-06946860, SC)lX X X X X
Anti-tumor therapy prescribed per SoCmX→→ →→→ →→→
Safety Labs (Blood and Urine): X X X X X X X X X X
Pregnancy Test for females (Blood and/or Urine)nX X X X X X X X X X
GDF-15 blood levels (Roche assay)oX
GDF-15 blood levels (Internal assa y(s))o,pX XXX XX X X X XXX X X X X
PF-06946860 serum PKpXXX XX X X X XXX X X X X
Immunogenicity (ADA/NAb)pXX X X X X X X X X
Prep D1 banked biospecimenqX
Prep B1.5 & B2 banked biospecimenqXX X X X XX X X X X
Patient Reported Outcomes (At home) (Cohort 1 
only)rX XXX XX X X X XXX X X
Patient Reported Outcomes (At clinic) (Cohort 1 
only)sX X X X X X X
 
Please see next page for table footnotes.  Abbreviations: see Appendix 21: Abbreviations .CCI
CCI
PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 15a. CT scan, and PROs (Cohort 1) are performed during the screening period to determine baseline values, but do not need to be
reviewed to determine eligibility.
b.Follow-up visits: Number, length, and frequency of follow-up visits may be modified based on emerging data.
c.At-Home visits : The blood sampling to be conducted at these visits is intended to be done at home by a visiting health care professional for t he participant’s 
convenience, but blood sampling may be conducted at the clinic, at the discretion of the participant or investigator. If the parti cipant will be coming to the 
clinic for clinical care on a day that a home visit is scheduled, the procedures for that visit can be performed at the clinic; a nd this will not be a protocol 
deviation.
d.AEs will be queried at each clinic visit using open-ended and nonleading verbal questioning of the participant.  Any spontaneously reported AEs noted 
during the home visits will be captured.
e.Full physical exam will be conducted at Screening.  Abbreviated physical exams planned at all other clinic visits, however full exams may be performed 
for findings during previous exam, new/open AEs, or at investigator discretion.
f.Triplicate blood pressure and pulse rate will be measured on Day 1; single blood pressure and pulse rate for all other clinic visits. See Section 8.2.3.
g.Triplicate ECGs on Day 1; single ECG for all other clinic visits. See Section 8.2.4 .
h. CT scan: If a CT scan was performed within 3 weeks prior to the Screening visit and meets the quality and anatomical requirements, then a CT scan at 
screening is not needed. If a CT scan is being performed at the Week 6 or Week 12 visit as part of the standard of care, then an additional CT scan is not 
needed as long as CT quality matches the requirements outlined in the imaging guidelines. The RECIST 1.1 categorization is to be entered in the CRF after 
each scan. See Section 8.1.2 .
i.CT scans can be done within ± 14 days of the Week 6 visit and within 7 days after the last dose of IP administration at the Week 12 visit.
j. CT scan: To be completed at the ET visit if a CT scan has not been completed in the prior 6 weeks.  However, a CT scan at the ET visit is not needed if the 
ET is before Week 4 or if a CT scan was performed at Week 12.
 
 
l.PF-06946860 dosing can be initiated at the start of the first or second cycle of the standard of care anti-tumor therapy.  If the standard of  care anti-tumor 
therapy is to be administered on the same day of dosing with  PF-06946860, the IP will be the first drug administered during the clinic visit and must be 
given at least 0.5h prior to administration of SOC anti-tumor therapy.  If SoC anti-tumor therapy is paused, adjusted or discon tinued during the 12 week 
treatment period, this would not be considered a protocol dev iation. PF-06946860  administration is to continue as prescribed by the protocol. 
m. The SoC anti-tumor therapy may continue beyond the study 12-week PF-06946860 treatment period according to the SOC anti-tumor therapy for each 
cancer type and the treating physician’s clinical judgment; this would not be considered a protocol deviation.
n.Blood and/or Urine pregnancy test may be performed at the discretion of the PI.
o. Two GDF-15 samples will be collected at Screening. One sample will be tested using the Roche GDF-15 assay for determination of enrollment eligibility.  
Another sample will be analyzed using the internal Pfizer GDF-15 assay(s).CCI
CCI
PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 16p.GDF-15, PK and Immunogenicity blood samples will be collected as described in Section 10.19 .  On dosing days (Day 1, Weeks 3, 6, 9, and 12), these 
blood samples will be collected prior to PF-06946860 administr ation (ie, pre-dose). Additionally, on Day 1 and Week 12, post-dose blood samples will be 
collected, one for PK and one for GDF-15 at each visit.  These post-dose blood samples will be collected at a minimum of 3h post PF-06946860 
administration or at a maximum by the end of the clinic visit.
q.Prep D1, B1.5 and B2 banked biospecimen samples collected during clinic visits will be collected prior to PF-06946860 administration. For Prep D1, if
not collected on the designated collection day, collect at the next available time point when biospecimens are being collected i n conjunction with a 
participant visit.
r. During Cohort 1, participants will be provided with a hand-held de vice at the Screening visit once the informed consent docume nt is signed and available 
eligibility criteria are confirmed for completion of  at home for daily completion between Screening and 
Week 18 , with a target of at least 7 consecutive days prior to Day 1 . The hand-held device is to be returned at Week 18 . 
 for details related to specific timing refer to Table 2 .  If the participant early terminates prior to  Week 18, the hand-held device is to be 
returned to the site. and for details related to specific timing refer to Table 2 .  If the participant early terminates pri or to Week 18, the hand-held device is to 
be returned to the site.
s. At each clinic visit during Cohort 1, participants will comp lete questionnaires on a separate electronic device (tablet) avail able at the site.  The devices will 
prompt the participant to complete the appropriate questionnaire(s). For additional details refer to Section 8.1.3 and for details related to specific timing 
refer to Table 2 .  If the participant early terminates prior to Week 18, the hand-held device is to be returned to the site.
 CCI
CCI
CCI
PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 172.INTRODUCTION
Cachexia is a metabo lic disorder and comorbidity that occu rs with several chronic diseases 
including cancer, heart failure, chronic obstructive pulmonary  disea se (COPD), and chronic 
kidney  disease (CKD).  Cachexia manifests as marked inv oluntary  body  weight loss, muscle 
atrop hy, and redu ced appetite, progressing to significant functional impairment and increased 
risk of death.
The cy tokine growth differentiatio n factor 15 ( GDF -15), also known as Macrophage 
Inhibitory  Cytokine 1 (MIC -1), is a member of the transforming growth factor beta (TGF) 
superfamil y.  In he althy  individuals the major source of circulating GDF -15 is belie ved to b e 
the liver, although it is also expre ssed by the kidney s, lung and adipose tissue ;1and during 
pregn ancy  it is highly  expressed by  placent al trophoblast .2GDF -15 is alsosecreted b y tumor 
cells, macropha ges and damaged cells.3-7  In several chronic conditions such as cancer, heart 
failure, COPD, and CKD, circulating GDF-15 c oncentr ations are markedl y elevated 
compared to healthy  levels.8-11  Elevated GDF -15 is associated w ith weight loss/cachexia in 
cancer12
-15and also heart failure16,17patients.  I n addition, elevated circulating GDF -15levels 
areassociated with poor outcome s and survival in many  cancers, heart failure, CKD and 
COPD.18-24  In rodents and non -human primates, GDF- 15 induces anorexia a nd weight 
loss25-29by acting through the glial cell- derived neu rotrophic factor (GDNF) family  recepto r 
alpha -like (GFRAL).  Furthermore, increased GDF -15 levels are a ssociate d with cachexia in 
mouse tumor models, and inhibition o f GDF -15 r everses weight loss and improves survival .14
GFRAL is a transmembrane pr otein with a short cy toplasmic domain lacking any  signaling 
funct ion and requires the ty rosine kinase co -receptor RET for signaling. Its expression is 
largel y restricted to the a rea postrema and the nucleus tractus so litarius. Signaling is 
mediated via d imers of circulating GDF -15 binding to a co- receptor complex comp osed of 
2 GFRAL molecules and 2 RET molecules leading to an a ctivated pentameric activated 
receptor complex.26-29
PF-06946860 is a r ecombinant humanized monoclonal antibody (immunoglo bulin ga mm a-1 
with kappa light chains [IgG1κ] ) directed ag ainst GDF -15.  This anti-GDF -15 humanized 
monoclonal antibody  (mAb) binds to the GDF -15 protein preventing its interaction with 
GFRAL.  It is anticipated that binding of the mAb to circulating GDF -15 will prevent its 
interaction with the GFRAL receptors an
d promote appetite and increase body  weight in 
patients with cac hexia. 
2.1.Study Rationale 
Non-Small Cell L ung Cancer (NSCLC) is a common ty pe of cancer with a high prevalence 
of cachexia.30NSC LC has been observed to be associated with elevated circulating GDF-15 
levels and this elevated conc entration of GDF -15 correlates with lower body  weight.13
Therefore, it i s hypothesized that cachexia in NSC LC is largel y media ted via GDF -15 and 
that suppression of GDF -15 in these patients may  lead to improvement in serious aspects of 
cachexia such as anorexia leading to unintended weight loss, fatigue and impaired mobility . 

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 18Simila r observations have been ma de i n other cance rs. Incolorectal cancer,elevations in 
GDF -15 have been reported as compared to levels in healthy  individuals ,and higher 
elevation correlate d with lower survival .31,32Elevated GDF -15 has also been reported in 
patients with pancreatic cancer .8Animal an d clinical data suggest that GDF - 15 is a key  
driver of cachexia in cancer ,and cachexia in pancr eatic cancer has been shown to correlate 
with decreased survival.33
This study  isintended to obtain safet y, tolerabilit y, pharmacokinetic ( PK)and
pharmacod ynamic ( PD)data following administration of PF - 0694686 0 to a limited number 
of partic ipants in the target patient population ,prior to exposure to a larger group of patients
with cancer and cachexia .  
2.2.Background
A summary  of releva nt, currentl y avail able data is provided in this protocol.  Additional
detail, and further information for th is compound ,may be found in the investigator ’s
brochure (IB). 
2.2.1. Nonclinical Pharmacology
PF-06946860 is a potent and highl y selective binder of hum an GDF -15 compared to 10 other 
human transforming growth factor beta ( TGF) family members.   In vitro binding ,to 
fragme nt cry stallizable gamma (Fc ) receptors , was not observed, suggesting low potential to 
cause antibod y dependent cell -mediated cy totoxicity  (ADCC) .
However, PF -06946860
elicited relatively low binding to C1q, sugge sting that the potential for 
complement -dependent cy totoxicity  (CDC) cannot be ruled out. PF-06946860 did not cause 
cytokine release in human w hole blood.
Consistent with the literature25-29exogenousl y administer ed mouse and human GDF -15 
caused weight loss (both lean mass and fatmass) in mice ,and administration of 
PF-06946860 reversed these observations. In a variety of GDF -15 secreting m ouse tumor 
models (HT -1080, PA0165, NSX -26115 and RENCA), tumor implantati on induced a 
cachectic phenot ypethatwas either prevented or reversed b y administration of PF -
06946860.  
Treatment with PF -06946860 also consistently  increased survival compared to control 
groups. Taken together, th e data s uggest that PF -06946860 has the potential to be a 
treatment for GDF -15 related cancer cachexia in humans.
2.2.2. Nonclinical Pharmacokinetics and Metabolism
Details of the nonclinical PKof PF -06946860 are provided in the IBSection 5.2.  The PK of 
PF-06946860 in mouse was consistent with that for a ty pical human immunoglobulin G1 
(IgG1) mAb.  After weekly
 subcutaneous (SC) administration of PF -06946860 to mice and 
monkey s in repeat dose toxicit y studie s,there were no apparent sex r elated differences in 
systemic exposure s, and accumulation was observed.   After repeat dosing, mean sy stemic 
exposure s increased in a less than dose proportional manner in mice and an approximately  
dose proportional m anner in monkey s.  PF- 06946860 did not induce inflammatory  cytokine 
release in vitro, therefore it is not expec ted to affect the PK of small molecule drugs either 

PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 19via cytokine mediated effects on CYP enzymes or transporters.  PF-06946860 is expected to 
undergo both non-specific proteolytic elimination and target-mediated elimination.  As such, concomitant medications and/or disease states, that alter the expression of GDF-15, may potentially impact the elimination of PF-06946860. 
2.2.3. Nonclinical Safety
PF-06946860 was administered weekly in SC studies for 13 weeks (3 months) to mice, and 
for 3- and 6-months to cynomolgus monkeys, followed by a recovery phase of approximately 2 and 3 months, respectively.  
No adverse effects were observed in any of the toxicity studies conducted with PF-06946860.
The cardiovascular and renal systems, and hematology parameters were identified as potential nonadverse targets. Cardiovascular and renal observations were predominantlyrelated to lower group mean organ weights but were nonadverse based on the small magnitude, lack of macroscopic, microscopic and functional correlates, and/or clinical sequelae. Hematology findings consisted of nonadverse increases in red blood cell massparameters.  Serum chemistry findings consisted of nonadverse increases in serum triglyceride concentration.  Other nonadverse findings related to administration of PF-06946860 included small magnitude alterations in clinical chemistry parameters, minor decreases in organ weights, zymogen granule depletion in the pancreas, minimal increases in locomotor activity in mice, and microscopic findings (mononuclear cell infiltrates of choroid plexus and glomerulus) considered secondary to antidrug antibodies (ADA) and immune complex disposition in monkeys. Nearly all of the dosing phase findings in both species reversed by the end of the recovery phase. 
The no-observed-adverse-effect levels (NOAELs) were the highest doses tested in the 
3-month study in mice  and the 3-month  and 6-month (20 mg/kg/week) studies in monkeys.  Systemic exposures of total PF-06946860 (maximumobserved concentration [C
max], average concentration [C av] and area under the curve from the 
time of dose administration up to 168 hours [AUC 168H]) at the NOAEL in the 3-month mouse 
study were 3190 μg/mL, 2010 μg/mL and 337,000 μg•h/mL, respectively. Systemic 
exposures of total PF-06946860 (C max,Cav, and AUC 168H) at the NOAEL in monkeys were 
5520μg/mL, 4340 μg/mL and 729,000 μg•h/mL, respectively, in the 3-month study and 
964μg/mL, 827 μg/mL and 139,000 μg•h/mL, respectively, in the 6-month study.
2.2.4. Clinical Overview
PF-06946860 has been evaluated in 2 completed Phase 1 single dose studies in healthy 
participants, C3651001 and C3651002.  Clinical data from the completed studies are provided in the IB for PF-06946860.CCI CCI
PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 22 
 
 
 
2.3. Benefit/Risk Assessment
This study is designed primarily to assess safety, tolerability, pharmacokinetics and 
pharmacodynamics of PF-06946860 in participants with non-small cell lung cancer, pancreatic cancer or colorectal cancer and cachexia.
The available clinical data show the single dosing of PF-06946860, in healthy participants, to 
be safe and well tolerated.  Efficacy has not yet been studied in humans.
Based upon pre-clinical data, it is possible that dosing with PF-06946860 will improve 
participants appetite and support maintenance of body weight; and there may be mitigation of the anorexia and emetogenic effect of platinum-based chemotherapy.
Considering all available clinical and nonclinical data, the benefit-risk profile of 
PF-06946860 is favorable and supports continued clinical development in patients with cancer and cachexia.
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events of PF-06946860 may be found in the investigator’s brochure (IB), which is the single reference safety document (SRSD) for this study.
3. OBJECTIVES AND ENDPOINTS
Objectives Endpoints
Primary: Primary: 
• To characterize the safety and tolerability of repeated 
subcutaneous administrations of PF-06946860 to participants with NSCLC, pancreatic cancer or colorectalcancer and cachexia.• Incidence of treatment emergent adverse events 
(AEs and SAEs), safety laboratory tests, vital signs (blood pressure and pulse rate) and standard ECG parameters (heart rate, QT, QTcF, 
PR and QRS intervals).
Secondary: Secondary: 
• To character ize unbound (free) and total PKof 
PF-06946860 administered to participants with NSCLC,pancreatic cancer or colorectal cancer and cachexia.• Serum unbound and total trough concentrations 
(C
trough) of PF-06946860 at Weeks 3, 6, 9, 12,
and 15.CCI
PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 23Tertiary/Exploratory: Tertiary/Exploratory: 
• To evaluate the immunogenicity profile of PF-06946860 
in participants with NSCLC, pancreatic cancer or
colorectal cancer and cachexia.• Incidence of ADA and NAb, if applicable.
• To characterize the effect of repeated administrations of 
PF-06946860 on circulating GDF-15 concentrations in 
participants with NSCLC, pancreatic cancer or colorectal cancer and cachexia.• Serum concentrations of total and, if feasible, 
unbound GDF-15 at time points specified in the schedule of activities (SoA) .
• To evaluate the effect of PF-06946860 on Lumbar 
Skeletal Muscle Index (LSMI) measured by CT scan in 
participants with NSCLC, pancreatic cancer or colorectal cancer and cachexia.• Change from baseline LSMI measured by CT 
scan at time points specified in the schedule of 
activities (SoA) . 
• To evaluate the effect of PF-09646860 on body weight in 
participants with NSCLC, pancreatic cancer or colorectal 
cancer and cachexia.• Change from baseline body weight at time points 
specified in the schedule of activities (SoA) .
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
  
 
 
• Cohort 1 only: To evaluate the effect of PF-06946860 on 
Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events ( PRO-CTCAE )
selected items in participants with NSCLC, pancreatic cancer or colorectal cancer and cachexia.• Change from baseline scores for selected 
PRO-CTCAE items at time points specified in Table 2 .
• Cohort 1 only: To evaluate the effect of PF-06946860 on 
fatigue as measured by the PROMIS-Fatigue
questionnaire in participants with NSCLC, pancreatic 
cancer or colorectal cancer and cachexia.• Change from baseline score for
PROMIS-Fatigue at time points specified in 
Table 2 .
• Cohort 1 only: To evaluate the effect of PF-06946860 on 
physical function as measured by the PROMIS-Physical 
Function questionnaire in participants with NSCLC,
pancreatic cancer or colorectal cancer and cachexia.• Change from baseline score for
PROMIS-Physical Function at time points specified in Table 2 .
• Cohort 1 only: To evaluate the effect of PF-06946860 on 
HRQoL as measured by FAACT in participants with 
NSCLC, pancreatic cancer or colorectal cancer and cachexia.• Change from baseline FAACT total and 
sub-scale scores at time points specified in Table 2 .
• Cohort 1 only: To evaluate the effect of PF-06946860 on 
Patient Global Impression of Severity ( PGI-S ) and Patient 
Global Impression of Change ( PGI-C ) in participants with • Change from baseline PGI-S at time points 
specified in Table 2 .CCI
PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 24NSCLC, pancreatic cancer or colorectal cancer and 
cachexia.• PGI-C at time points specified in Table 2 .
 
  
 
 
  
 
• To evaluate the effect of PF-06946860 on ability to 
complete anti-tumor treatment as originally prescribed 
in participants with NSCLC, pancreatic cancer orcolorectal cancer and cachexia.• Number and % of participants completing 
anti-tumor treatment as originally prescribed.
• To evaluate the effect of PF-06946860 on participant 
survival in participants with NSCLC, pancreatic cancer or
colorectal cancer and cachexia.• Number and % of participants alive at last 
subject last visit (LSLV).
• To evaluate tumor burden in participants with NSCLC,
pancreatic cancer or colorectal cancer and cachexia.• The RECIST 1.1 categorization using CT scan at 
time points specified in the schedule of activities 
(SoA) . 
• To enable exploratory research through collection of 
banked biospecimens , unless prohibited by local 
regulations or ethics committee decision.• Potential results from exploratory analysis of 
banked biospecimens (these results may or may 
not be generated in the context of the present 
study).
4. STUDY DESIGN
4.1. Overall DesignThis is a Phase 1b, open-label study in participants with advanced metastatic NSCLC,
pancreatic cancer or colorectal cancer and cachexia, and elevated circulating GDF-15 concentrations. Baseline GDF-15 levels will be assessed at screening to determine eligibility for participation.
Following the 28-day screening period to confirm eligibility, the study will consist of a 
treatment period of 12weeks and a follow-up period of 12weeks.  The total duration of participation in this study is approximately 24 weeks (not including the screening period).
During the 12-week treatment period in Cohort 1, participants will receive a total of 5 doses 
of PF-06946860, administered subcutaneously (SC), every 3 weeks (Q3W).  
This study will consist of up to 2 cohorts.  In each study cohort, approximately 8 participants
will be enrolled such that approximately 6 evaluable participants complete the study.Participants who discontinue prior to completion of the study may be replaced, at the discretion of the investigator and sponsor.  It is planned that the 2 cohorts will be enrolled sequentially and will follow similar schedules of activity.  The optional Cohort 2 may be conducted at the discretion of the Sponsor, with data emerging from Cohort 1 informing the dose level and/or frequency to be administered in Cohort 2 (see Section 4.3 ).  CCI
PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 25Based on emerging data, the dose, schedule, length and number of follow-up visits required 
may be adjusted; in this case, details will be provided to the investigator in writing or via a protocol amendment, as appropriate, prior to initiation of the cohort.
4.2. Scientific Rationale for Study Design
The purpose of this study is to evaluate the safety, tolerability, PK, PD and immunogenicity 
of PF-06946860 following repeated SC administrations to adult patients with advanced metastatic NSCLC, pancreatic cancer or colorectal cancer and cachexia, with elevated concentrations of circulating GDF-15. 
Elevated concentrations of circulating GDF-15 have been reported in literature
12-15,in 
patients experiencing weight loss with a variety of tumor types (including lung cancer) and a greater magnitude of elevation was associated with worse survival. Biospecimens from healthy adults
34and patients with cancer (from both external commercial biorepositories and
an internal study) were analyzed for GDF-15 concentrations.  The cancer sample set contained 399 NSCLC, 116 pancreatic cancer, and 157 colorectal cancer patients.  These patients were mostly Caucasian, aged 29-90, and had an approximate ratio of 40%:60% females to males.  The sample set of 739 apparently healthy volunteers were predominantly Caucasian, aged 20-79 and equally distributed males and females. Analysis of both the cancer and healthy sample sets using the Roche Elecsys assay,
34confirmed 
literature reported elevations in GDF-15 concentrations in NSCLC, pancreatic cancer, and colorectal cancer patients in comparison to healthy subjects (approximately 4-fold, 5-fold,and 4-fold, respectively).  An ad-hoc analysis of samples from NSCLC patients from an internal Pfizer study demonstrated that higher GDF-15 concentrations were associated with a reduction in body weight.  These data were also used to determine the degree of GDF-15 elevation necessary for inclusion in this study. GDF-15 concentrations above the 95
th
percentile of GDF-15 concentrations reported in these healthy subjects will be considered elevated ( ≥ ).  
In addition, published clinical data and internal animal model data suggest that 
administration of platinum therapy can induce increases in serum GDF-15 concentrations.Clinical literature and internal animal model data
35also suggest that the nausea, emesis and 
anorexia observed with platinum therapy may be mediated, at least in part, by platinum-induced elevations in GDF-15. 
Therefore, it is hypothesized that cachexia in many types of cancer, including NSCLC, 
pancreatic cancer, and colorectal cancer, is largely mediated via GDF-15 and that suppression of GDF-15 in these patients may lead to improvement in serious aspects of cachexia such as anorexia leading to unintended weight loss, fatigue and impaired mobility.  Furthermore, given the observations of GDF-15 elevation with platinum therapy, patients receiving standard of care anti-tumor treatment that includes systemic platinum-based therapy, may be a specific population that could potentially gather additional benefit from GDF-15 inhibition. CCI
PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 26Study C3651009 represents the first administration of PF-06946860 in patients with cancer
and cachexia.  As such, an open-label design and a small sample size have been implementedin order to transparently establish an initial assessment of clinical safety, PK, PD and immunogenicity of this novel therapy.
A treatment duration of 12 weeks is consistent with available pre-clinical toxicology 
coverage and to support development of PF-06946860 in subsequent Phase 2 studies.  A treatment duration of 12 weeks should provide sufficient safety information to inform subsequent PF-06946860 Phase 2 studies.  After the 12-week treatment period, participants will be followed up for 12 weeks post last dose. Based on the preliminary population PK/PD simulation results, it is anticipated that at 12 weeks post last dose of  PF-06946860the unbound PF-06946860 concentrations will be below the level that would be expected to fully suppress GDF-15.
PF-06946860 will be dosed via subcutaneous injections, every 3 weeks. However, the 
dosing frequency in Cohort 2 may be adjusted based upon emerging data from Cohort 1.
In addition to the characterization of safety, tolerability, PK, PD and immunogenicity of 
PF-06946860, this study will include exploratory assessment of key parameters needed in future studies to characterize the efficacy of PF-06946860. Cachexia is characterized by involuntary anorexia and weight loss, involving skeletal muscle mass depletion. Therefore,body composition via CT-scan derived lumbar skeletal index will be measured. In addition to lumbar skeletal muscle index, assessment of the impact of PF-06946860 on other aspects of cachexia, will be studied. These will be measured through the use of electronic Patient Reported Outcome (ePRO) instruments administered to patients at home and during clinic visits. These initial exploratory data will be collected during Cohort 1 and will be used to start the process of validation of these instruments for use in the clinical development in the target population (cancer patients with cachexia). Validation of these instruments in early studies will enable a better assessment of the effect of PF-06946860 on how patients feel. 
 
 
 
 
 
 
The baseline assessments for the CT scan-derived LSMI,  and PROs will be
performed during the screening period, but do not need to be reviewed to determine eligibility.CCI
CCI
CCI
CCI
PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 27PF-06946860 dosing can be initiated at the start of a participant’s first or second cycle of 
standard of care anti-tumor therapy. Flexibility in the initiation of PF-06946860 is intended to minimize any interference with the evaluation, diagnosis, and/or initiation of standard of care anti-tumor therapy.  
At the present time, embryo-fetal developmental toxicology studies with PF-06946860 have 
not been conducted.  Consequently, to prevent pregnancy, the protocol includes contraceptive provisions for both male and female participants (see Section 5.3.1 andAppendix 4
Section 10.4.4 ).
Banked biospecimens will be collected for exploratory 
pharmacogenomic/genomic/biomarker analyses and retained in the Biospecimen Banking System (BBS), which makes it possible to better understand the investigational product’s mechanism of action and to seek explanations for differences in, for example, exposure, tolerability, safety, and/or efficacy not anticipated prior to the beginning of the study.
4.3. Justification for Dose
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  CCI
PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4. End of Study Definition
A participant is considered to have completed the study if he/she has completed all phases of 
the study including the last follow up visit.CCI
CCI
PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 29The end of the study is defined as the date of the last visit of the last participant in the study.
5. STUDY POPULATION
This study can fulfill its objectives only if appropriate participants are enrolled.  The 
following eligibility criteria are designed to select participants for whom participation in the study is considered appropriate.  All relevant medical and nonmedical conditions should be taken into consideration when deciding whether a particular participant is suitable for this protocol.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
Age and Sex:
1. Male or female participants ≥18 years of age (or the minimum country-specific age of 
consent if >18), at screening.
•Refer to Appendix 4 for reproductive criteria for male ( Section 10.4.1 ) and female
(Section 10.4.2 ).
Type of Participant and Disease Characteristics:
2. Participants who are willing and able to comply with all scheduled visits, treatment 
plan, laboratory tests, lifestyle considerations, and other study procedures.
3. Documented histologic or cytologic diagnosis of advanced metastatic NSCLC, 
advanced/unresectable pancreatic cancer, or metastatic colorectal cancer by American Joint Committee on Cancer (AJCC) criteria
4. Cachexia, defined using Fearon’s criteria:
36
•Body Mass Index (BMI) <20 kg/m2with involuntary weight loss of >2% within 
6 months prior to screening; or 
•Involuntary weight loss of >5% within 6 months prior to screening irrespective of 
BMI; or
If medical record documentation is unavailable, patient’s report will suffice to 
estimate involuntary body weight loss.
5. Serum GDF-15 levels of ≥ (as measured using the Investigational Use Only
Roche Elecsys GDF-15 assay34) at screening.CCI
PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 306.Participants considered eligible for systemic anti -cancer treatment /therap y at the time 
of screening, who:
Are diagnosed with advanced metastatic NSCLC who will be treated with: 
Aplatin um+ pemetrexed ± pembrolizumab; or 
Aplatin um+ nab paclitaxel or paclitaxel ±pembrolizumab; or 
Pembro lizumab alone .
Are diagnosed with advanced /unresectable pancreatic cancer who will be treated 
with:
FOLF IRINOX; or
Nab-Paclitaxel + Gemcitabine;
Gemcitabine .
Are diagnosed with metastatic colorectal cancer who will be treated with:
FOLFOX +/ -Biologic ( Bevacizumab or Cetuximab /Panitumumab); or
FOLFIRI +/ -Biologic ( Bevacizuma b or Cetuximab/Panitumumab ); or
FOLFOXIRI +/-Biologic ( Bevacizumab or Cetuximab /Panitumumab ); or
Pembrolizumab for MSI -H.
Will be e ntering the study at the first or second cycle of their current course of 
anti-cancer treatment/ therapy . 
Note: Other therap iescan be considered upon discussion with the Pfizer medical 
monitor .
7.Adequate liver function as evidenced b y liver enzymes, including :
Total serum bilirubin ≤1.5 x upper limit of normal ( ULN )unless the parti cipant 
has documented Gilbert syndrome;
Aspartate and Alanine aminotransferase (AST and AL T) ≤2.5 x UL N; 
≤5.0 x ULN if there is liver involvement b y the tumor; 
Alkaline phosphatase ≤ 2.5 x ULN ( ≤5 x UL Nincase of bone metastasis). 

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 318.Adequate renal function, including creatinine ≤2mg/dL, or Glomerular Filtration 
Rate (GFR) ) ≥30 mL /minute /1.73 m2as calculated by the modification of diet in 
renal disease (MDRD) equation37(Appendix 18).
Weight: Not Applicable (N/A)
Informed Consent:
9. Capable of giving signed informed consent as described in Appendix 1 ,which 
includes complian ce with the requ irements and restrictions listed in the informed 
consent document (ICD) and in this protocol.
5.2.Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.All other forms of cancer snot specified in Inclusion Criteri on #3 unless currentl y 
considered c ured (>5 years without evidenc eof recurrence).
2.Participants with known sy mptomatic brai n metastases requiring steroids. 
Participants with asy mptomat ic or previousl y diagnosed brain metastases are eligible 
if they  have completed thei r treatment and have recovered from the acute effects of 
radiation therap y or surgery  prior to screening , have discontinued corticosteroid 
treatment for these metastases and are n eurologically  stable for at least 4 weeks
(requires magnetic resonance imaging [MRI ] confirmation) prior to randomization .  
3.Planned radiation therapy  as part of the primary  anti- tumor therap y regimen.  
However , localized radiation therapy  for s ymptomatic relief is permitted and if this
becomes necessary  after randomization, it will not be a reason for discontinuation.
4.Other acute or chronic medical or ps ychiatric condition including recent (within the 
past y ear) or active suicidal ideation or behavior or l aboratory  abnormality  that may  
increase the risk associated with study  participation or investigational product 
administration or may  interfere with the interpretation of study  results and, in the 
judgment of t he investigator, would make the participant in appropriat e for entry  into 
this study .
5. Active hepatitis B virus (HBV) or hepatitis C virus (HCV).
6.Confirmed positive test for human immunodeficiency  virus (HIV).
7.Current active rever sible causes of decreased food intake, as determined by  the 
Investigator. These caus es may  include, but are not limited to:

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 32National Cancer Institute (NCI)Common Terminology  Criteria for Adverse 
Events ( CTCAE )Grade 3 or 4 oral mucositis;
NCI CTCAE Grade 3 or 4 Gastrointestinal (GI) disorders [nausea, vomiting, 
diarrhea, and co nstipation] ;
mechanical obstructions making patient unable to eat.
8. R eceiving tube feedings or parenteral nutrition (either total or partial) at the time of 
Screening .
9.Undergoing major surgery  (central venous ac cess placement and tumor biopsies are 
not considered major surgery ) within 4 weeks prior to randomization. Patient must be 
well recovered from acute effects of surgery  prior to screening. Patient should not 
have plans to undergo major surgical procedures during the study .
10. Severe gastrointestinal disease (including esophagitis, gastritis, malabsorption).
11.History  of gastrectomy .
12.Cachexia caused b y other reasons, as determined by the investigator, including, but 
not limited to: 
Severe COPD requiring use of home O 2;
New York Heart Association (NYHA) cla ss III -IV heart failure ;
Acquired Immunodeficiency  Syndrome ( AIDS).
13.Any of the following in the previous 6 months: myocardial infarction, congenital long 
QT sy ndrome, Torsade de Pointes, arrhy thmias (including sustained ventricular 
tachyarrh ythmia and vent ricular fibrillation), unstable angina, coronary /peripheral 
artery  bypass graft, s ymptomatic congestive heart failure (CHF, New York Heart 
Association class III or IV), cerebrovascular accident , transient ische mic attack, or 
symptomatic pulmonary  embolism or other clinical significant episode of thrombo 
embolic disease. 
Ongoing cardiac d ysrhythmias of National Cancer Institute (NCI) CTCAE 
Grade ≥
2. 
Prior/Concomitant Therapy:
14.Actively  receiving a concurrent investigational agent or previous administration 
with 
an investigational drug within 30 days (or as determined by  the local requirement) or 
5half-lives preceding the first dose of investigational product used in this study  
(whichever is longer).

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 33Prior/C oncurrent Clinical Study Experience:
15.Enrollment in a pre vious study  with PF - 06946860.
Diagnostic A ssessments:
16.Elevated blood pressure that cannot be controlled by  medications 
(eg,>150/90 mmHg) desp ite optimal medical therapy .
Other Exclusions:
17.Woma n who is pregnant or breast -feeding.
18. Investigat orsite sta ff members directl y involved in the conduct of the study and their 
family  members, site staff members otherwise supervised by  the investigator , or 
Pfizer employ ees, including their family  members, directly  involved in the conduct of 
the study .
5.3.Lifestyle C onsiderations
5.3.1. Contraception
The investigator or his or her designee, in consultation with the participant , will confirm that 
the participant has s elected an appropriate method of contraception for the individual 
participant and his or her partner (s)from the permitted list of contraception methods (see 
Appendix 4 Section 10.4.4 ) and will confirm that the participant has been instructed in its 
consis tent and correct use.  At time points indicated in the , the investigator or designee will 
inform the participant of the need to use highl y effecti ve contraception consistently  and 
correctly  and document the conversation and the participant ’s affirmation i n the participant ’s 
chart ( participant s need to affirm their consistent and correct use of at least 1 of the selected
methods of contraception).  I n addition, the investigator or designee will instruct the 
participant to call immediately  if the selected co ntraception method is discontinued or if 
pregnancy  is known or suspected in the participant or partner ,the investi gator or designee 
will inform the participant of the need to use highly  effective contraception consistently  and 
correctly  and document the c onversation and the participant ’s affirmation in the participant ’s 
chart ( participant s need to affirm their consist ent and correct use of at leas t 1 of the selected 
methods of contraception).  In addition, the investigator or designee will instruct the 
participant to call immediately  if the selected contraception method is discontinued or if 
pregnancy  is known or suspe cted in the participant or par tner.
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical st udy but 
are not subsequently  entered in the study . A minimal set of screen failure information is 
required to ensu re transparent reporting of sc reen failure participants to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requireme nts and to 
respond to queries from regulatory  authorities. Minimal information includes demography , 
screen failure details, eligibility  criteria , and any  serious adverse event (SAE).

PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 34Individuals who do not meet the criteria for participation in this study (screen failure) may 
not be rescreened. 
6. STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant according to the study protocol.
For the purposes of this protocol, the term investigational product may be used 
synonymously with study intervention.
6.1. Study Intervention(s) Administered
Intervention Name PF-06946860 PF-06946860
ARM Name PF-06946860 Cohort 1 PF-06946860 Cohort 2 
Type Biologic Biologic
Dose Formulation Solution for injection Solution for injection
Unit Dose Strength(s)  and diluent TBD 
Dosage Level(s)  Q3W TBD 
Route of Administration Subcutaneous Subcutaneous 
Investigational Medicinal Product (IMP) 
and Noninvestigational Medicinal 
Product (NIMP)IMP IMP
Sourcing Provided centrally by the 
sponsorProvided centrally by the 
sponsor
Packaging and Labeling Study intervention will be 
provided in 6-mL glass vial with a 1 mL withdraw volume.  Each vial will be labeled as 
required per country
requirement.Study intervention will be 
provided in 6-mL glass vial with a 1 mL withdraw volume.  Each vial will be 
labeled as required per 
country requirement.
Current/Former Name(s) or Alias(es) Not applicable Not applicableCCI
CCI
PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 356.1.1. Administration
During all clinic visits, the dose of investigational product must be administered in the off ice 
by study  personnel .  PF- 06946860 is to be administered first, followed b y any 
premedications administered at the clinic (eg, 
antihistamine, anti- inflammatory  agent, or pain 
reliever) and then the standard of care prescribed anti -tumor therap y.If the standard of care
anti-tumor therap y is to be administered on the same day  of dosing with PF -06946860, 
PF-06946860 will be the first drug administered during the clinic visit and must be given at 
least 0.5h prior to administration of thestandard of car e anti-tumor therapy . If the standard 
of care anti-tumor therapy  is paused, adjusted or discontinued during the 12 -week treatmen
t 
period, this would not be considered a protocol deviation. PF-06946860 administration is to 
continue as prescribed b y the protocol.  The standard of care anti-tumor therapy  may  either 
be shorter or may  continue bey ond the study  12week PF -06946860 treat ment period 
according to 
the standard of care anti-tumor ther apy for each cancer ty pe and the treating 
physician’s cl inical judgment; this would not be considered a protocol deviation .Similarly , 
adjustments to the standa rd of care anti-tumor therapy  dose or duration , including treatment 
holiday s are at the discretion of the PI . 
Premedication is permitted for all parti cipants, consistent with institutional guidelines, and 
may include an antihistamine, anti
-inflammatory  agent ,or pain reliever.
6.2.Preparation /Handling/St orage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  intervention sreceived and an y 
discrepancies are reported and resolved before use of the study  intervention ,as 
applicable for temperature -monitored shipments . 
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention. All study 
intervention s must be stored in a secure, environmentally  controlled, and monitored 
(manual or automated recording ) area in accordance with the labele d storage 
conditions with access limited to the investigator and authorized site staff.  At a 
minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request.  Data for nonworking days must 
indic atethe minimum and maximum temperature since previousl y documented for all 
site storage locations upon return to business.
3.The investigato r, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability , reconciliation, and record 
maintenance (i e, receipt, reconciliation, and final disposition records). All study  
interventions will be accounted for using a ninvestigational product accountability  
form/record.  
4. Further guidance and information for the final disposition of unused study  
interventions are provided in the investigational product ( IP) manual.

PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 365. Any storage conditions stated in the SRSD will be superseded by the storage 
conditions stated on the product label. 
6. Study interventions should be stored in their original containers and in accordance 
with the labels. 
7. See the IP manual for storage conditions of the study intervention.8. Any excursions from the study intervention label storage conditions should be 
reported to Pfizer upon discovery along with any actions taken. The site should actively pursue options for returning the study intervention to the storage conditions described in the labeling, as soon as possible. Once an excursion is identified, the study intervention must be quarantined and not used until Pfizer provides permission to use the study intervention.  It will not be considered a protocol deviation if Pfizer approves the use of the study intervention after the temperature excursion. Use of the study intervention prior to Pfizer approval will be considered a protocol deviation. Specific details regarding the definition of an excursion and information the site should report for each excursion will be provided to the site in the IP manual.
9. The sponsor or designee will provide guidance on the destruction of unused study 
intervention (eg, at the site).  If destruction is authorized to take place at the investigator site, the investigator must ensure that the materials are destroyed in compliance with applicable environmental regulations, institutional policy, and any special instructions provided by Pfizer, and all destruction must be adequately documented.
Additional details about accountability, storage, destruction, and excursion reporting can be 
found in the IP manual.
6.2.1. Preparation and Dispensing
Investigational Product, PF-06946860 ( ), and diluent (depending upon the dose)
will be used to prepare doses for administration.  See the IP manual for instructions on how to prepare the investigational product for administration.  Investigational product should be prepared and dispensed by an appropriately qualified and experienced member of the study staff (eg, physician, nurse, physician’s assistant, nurse practitioner, pharmacy assistant/technician, or pharmacist) as allowed by local, state, and institutional guidance.
6.3. Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Investigational Product
This is an open-label study; however, the specific investigational product dispensed to the 
participant will be assigned using an interactive response technology (IRT) system (interactive Web-based response [IWR]). The site will contact the IRT prior to the start of investigational product administration for each participant.  The site personnel (study coordinator or specified designee) will be required to enter or select information including but not limited to the user’s identification (ID) and password, the protocol number, and the 
CCI
PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 37participant number.  The site personnel will then be provided with a treatment assignm ent, 
randomization number, and dispensable unit (DU) or container number when investigational 
product is being supplied via the I RT s ystem.  The I RT s ystem will provide a confirmation 
report containing the participant number, randomization number, and DU o r container 
number assigned.  The confirmation report must be stored in the site’s files. The site will 
record the investigational product assignment on the applicable case report form, if required.  
Investigational product will be dispensed at the clinic study  visits as summarized in the SoA . 
The study -specific I RT reference manual and I P manual will provide the conta ct information 
and further details on the use of the IRT s ystem.
6.4. Study Intervention Compliance
All doses of investi gational product will be administered by  the appropriately  designated 
study staff at the investigator site.
6.5. Concomitant Therapy
Participants may be entering the study  at the first or second cy cle of their current course of 
standard of care anti-tumor thera py. Participants will receive standard of care anti- tumor 
therap y as described in the Inclusion criteria (See Section 5.1) andwill receive an y other 
supportive treatments or in terventions as indicated by  standard of care for their clinical 
condition. 
Hormonal contraceptives ,that meet the requirements of this study ,are allowed to be used in 
participants who are women of childb earing potential ( WOCBP
) (see Appendix 4 ).
Concomitant treatment considered necessary  for the participant’s well- being may  be given at 
discretion of the treating physician.  
All concomitant treatments, blood p roducts, as well as nondrug interventions 
(eg,paracentesis) received by  participants from screening until the end of study  visit will be 
recorded on the case report form ( CRF )with indication, daily  dose, a nd start and stop dates 
of administration.  All p articipants will be questioned about concomitant t reatment at each 
clinic visit. 
Treatments taken within the 28 days before the first dose of I P will be documented as a prior 
treatment.  Treatments taken af ter the first dose of I P will be documented as a concomitant 
treatment.
6.6. Dose Modification
There is no dose modification of PF -06946860 anticipated for a given participant in this 
study .

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 386.7.Intervention A fter the End of the Study
No intervention will be provi ded to study  participants at the end of the study .
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTIC IPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
In rare instances, it may  be necessary  for a participant to permanentl y discontinue 
investigational product . If investigational p
roduct is permanentl y discontinued, the 
participant will remain in the study  for follow up. Note that discontinuation of 
investigational product does not represent withdrawal from the stud y.
If a safet y or toler ability  concern arises, in particular if not responsive to s
ymptomatic
management, dosing with I P may  be stopped in an individual participant at investigator 
discretion .
Any participant who prematurely  withdraws after being randomized and during active study  
intervention, (Day 1 through Week 12) sho uld return for an early withdrawal visit and then 
enter into the follow -up period.
See Section 1.3 for data to be collected at the time of intervention discontinuation and
follow -upand for any further evaluations that need to be completed .
7.1.1. Criteria for Discontinuati on 
Discontinuation of IP must occur for a participant meeting any  of the following con ditions: 
Criteria for a potential Hy ’s law case are met (see Appendix 6 ).
Intent to become pregnant or pregnancy  confirmed by  serum beta human chorionic
gonadotropin (-hCG) testing.
7.2.Participant Discontinuation/ Withdr awal from the Study
A participant may  withdraw from the study  at an ytime at his/her own request.  Reasons for 
discontinuation from the study  include the following:
Refused further follow -up;
Lost to follow -up;
Death ;
Study  terminated by  sponsor .

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 39At the time of discontinuing from the stud y, if possible, an earl y discontinu ation visit should 
be conducted.  See the SoA for assessments to be collected at the time of study  
discontinuation and follow- up and for an y further evaluat ions that need to be completed.
If a participant withdraws from the study , he/she may  request destruction of any  remaining 
samples taken and not tested, and the investigator m ust document any  such requests in the 
site study  records and notify  the sponsor a ccordingly .
If the participant withdraws from the study  and also withdraws c onsent ( see Section 7.2) for 
disclosure of future information, no further evaluations should be performed and no 
additional data should be collected.  The sponsor may  retain and continue to use any data 
collected before such withdrawal of consent.
Lack of completion of all or a ny of the withdrawal /early termination procedures will not be 
viewed as protocol deviations so long as the participant’s safet y was preserved.
Withdrawal of Consent: 
Parti cipant s who request to discontinue receipt of study  treatment will remain in the stu
dy 
and must continue to be followed for protocol -specified follow -up procedures.  The onl y 
exception to this is when a participant specificall y withdraws consent for any fu rther contact 
with him or her or persons previously  authorized by  the participant toprovide this 
information.  Participant s should notify  the investigator in writing of the decision to 
withdraw consent from future follow -up, whenever possible.  The withdr awal of consent 
should be explained in detail in the medical records by  the investig ator, as to whether the 
withdrawal is only  from further receipt of investigational product or also from study  
procedures and/or posttreatment study  follow -up, and entered on the appropriate CRF page.  
In the event that vital status (whether the participant is alive or dead) is being measured, 
publicly  available information should be used to determine vital status only as appropriatel y 
directed in accordance with local law.
7.3. L ost to Follow-up 
A participant will be considered lost to follow- up if he or she re peatedl y fails to return for 
scheduled visits and is unable to be contacted b y the study  site.
The following actions must be taken if a participant fails to return to the c linic for a required 
study  visit:
The site must attempt to contact the participant a nd reschedule the missed visit as 
soon as possible and counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether or not the participant wishes to and/or 
should continue in the study ;

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 40Before a participant is deemed lost to follow -up, the investigator or designee must 
make every  effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary , acertified letter to the participant’s last known mailing 
address or local equivalen t methods). These contact attempts should be documented 
in the participant’s medical record ;
Should the participant continue to b e unreachable, he/she will be considered to have 
withdrawn from the study. 
Discontinuation of specific sites or of the study  
as a whole ishandled as part of Appendix 1.
8.STUDY ASSESSMENTS AN
D PROCEDURES
The inve stigator (or an appropriate delegate at t he investigator site) must obtain a signed and 
dated ICD before performing any  study -specific procedures.  
Study  procedures and their timing are summarized in the SoA. Refer to Appendix 1 9fora 
proposed chronology  of procedures. Protocol waivers or exemptions are not allowed.
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or disconti nue study  
intervention.
Adherence to the stu dy design requirements, including those specified i n the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potentia l 
participants meet all eligibility  criteria . The investigator will m aintain a screening log to
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Every  effort should be made to e nsure that protocol -required tests and proce dures are 
completed as des cribed.  However, it is anticipated that from time to time there may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test.  I n these c ases, the investigator must take all steps n ecessary  to ensure the saf ety and 
well-being of the participant.  When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive
actions that he or she has taken to ensure that required processes ar e adhered to as soon as 
possible.  The study  team must be informed of these incidents in a timely  manner.
Any changes in the timing or addition of time points (eg, additional follow up v isits) for an y 
planned study assessments mus t be documented and ap proved b y the relevant study  team 
member and then archived in the sponsor and site study  files, but will not constitute a 
protocol amendment.  The I RB/EC will be informed of any  safet y issue s that require 
alteration of the safet y monitoring scheme or amend ment of the I CD.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 41For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator sit e prior 
to initiation of the study .
The tota l blood sampling volu
me for individual participant s in this study  is approximately  
490mL.  The actual collection times of blood sampling may  change.  Additional blood 
samples may  be taken for safet y assessme nts at times specified b y Pfizer, pro
vided the t otal 
volume taken during the study  does not exceed 550 mL during an y period of 60 consecutive 
days.
8.1.Efficacy Assessments
The following procedures will be conducted as part of exploratory  assessments .
8.1.1. Body Wei ght
Weight will be recorded using a c alibrated s cale (with the sam e scale used if possible for the 
duration of the study ) reporting weight in either pounds (lb.) or kilograms (kg), and accuracy  
to the nearest 0.2 lb. (or 0.1 kg); ie, the device must be abl e todistinguish a difference 
between 150.4 lb. (68.4 kg) versus 1 50.2 lb. (68.3 kg).  The scale must be placed on a stable, 
flat surface.
Weight measurement should be taken under the following conditions:
After void of urine ;
After removal of shoes, bulky layers of clothing and jackets so th at only  light clothing 
remains;
While remaining still during the measurement .
8.1.2. Imaging Assessment
8.1.2.1. CT Scan
CT scans will be acqu ired throughout the study  to monitor the tumor burden and evalu ate the 
Lumbar Skeletal Musc le Index ,in addition to other potential explora tory muscle quality  
parameters.  The standard process to obtain serial CT scans will be outlined in an I mage 
Acquisition Manual.  The sites will be provided w ith guidance onobtaining CT images of the 
chest, abdomen, and pelvis that meet the quality  requir ement of this study .  
If a CT scan was performed within 3 weeks prior to the Screening visit and meets the quality  
and anatomical requirements, then a CT s can at screening is not needed. If a CT scan was 
not pe rformed prior to Screening, a CT scan should be performed after other eligibility  
criteria (such as medical history , diagnosis )have been confirmed .  The CT scan may  be 
performed without receipt of safety laboratory  and GDF -15 sample results.  If a CT scanis 
being performed at the Week 6 or Week 12 visit as part of the standard of care, then an 

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 42additional CT scan is not needed as long as CT scan quality  matches the requirements 
outlined in the I mage A cquisition Manual.
Monitoring of the tumor burden wi ll be performed by the local imaging site follow ing 
standard RECI ST1.1criteria (outlined in Appendix 17). TheRECI ST 1.1 categorization i s 
to be entered in the CRF after each scan.
CT scans will also be required to be sent to a central imaging review facility  for evaluation of
the L umbar Skeletal Muscle Index and exploratory  measures of muscl e quality .  Central 
image review is not a complet e medical review of the participant and will not include any  
tumor assessme nts.  If, during the central review process, an unexpected observation is 
identified and this finding could, in the opinion of the c entral reviewer, have a significant 
health or reproductive consequence, this finding may  be shared with the study  sponsor fo r 
disclosure to the principal investigator (PI).   All follow up testing and final diagnosis will be 
left to the discretion of the me dical professionals at the site or t hose with an existing 
physician participant relationship.  The PI  will be responsible for re porting any  AEs 
identified from incidental findings as described in the AE reporting section.  I dentific ation of 
such incidental findings dur
ing the central review process should not be expected, and the 
site maintains responsib ility for performing a general safet y review of all images as per site 
protocols.
8.1.3. Patient -Reported Outcomes (Cohort 1)
All patient -reported outcome (PRO) assessments are implemented on anePRO device 
(hand -held device for home use and tablet for clinic use ) and completed by study  participants 
at home, or at the clinic ,following a schedule of assessments as per the SoA and Table 2. 
Every  effort should be made to have the study  participant complete all patien t-reported 
outcome assessments before an y other clinical assessments that tak e place at the clinical site.  
The site user guide will be provided separatel y.

PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 43Table 2. Patient Reported Outcomes for Cohort 1
Patient Reported Outcome (PRO) 
Measure PlannedFrequency Assessment Number of 
QuestionsCompletion 
Time
 
 
  
 
PRO-CTCAE selected items: taste change, decreased appetite, fatigue, nausea, vomitingConducted at clinic visits on Day 1 
(Baseline), Week 3, Week 6, Week 9, Week 12 and Week 18At the clinic 9 ~3 minutes
Patient Global Impression of Severity 
(PGI-S) (1 item: appetite) Conducted at clinic visits on Day 1 
(Baseline), Week 3, Week 6, Week 9, Week 12 and Week 181
Patient Global Impression of Change 
(PGI-C) (2 items: appetite and fatigue)Conducted at clinic visits on Week 12 
and Week 182
PROMIS-Fatigue 7a (“Past 7 days” 
recall version)Conducted at clinic visits on Day 1 
(Baseline), Week 6, Week 12, and 
Week 18 7 ~14 minutes
PROMIS-Physical Function 8c 
(no recall version)Conducted at clinic visits on Day 1 
(Baseline), Week 6, Week 12, and 
Week 188
FAACT Conducted at clinic visits on Day 1 
(Baseline), Week 6, Week 12, and 
Week 1839
 
 
 
 
 
8.1.3.2. Patient-Reported Outcomes Version of the Common Terminology Criteria for 
Adverse Events (PRO-CTCAE™)
Initiated and sponsored by the US National Cancer Institute, the PRO-CTCAE ( Appendix 9 ) 
is a patient-reported outcome measure developed to evaluate symptomatic toxicity in patients enrolled in cancer clinical trials. It was designed to complement the Common Terminology Criteria for Adverse Events (CTCAE), the standard lexicon for investigator or clinician-reported adverse events in cancer trials. The PRO-CTCAE item library is composed of 124 self-report items reflecting 78 symptomatic adverse events drawn from the CTCAE arranged by organs and systems. Each adverse event is assessed relative to one or more attributes that include the presence/absence/amount (P), frequency (F), severity (S), and interference (I) with usual or daily activities. PRO-CTCAE provides a systematic yet flexible tool for descriptive reporting of symptomatic treatment side effects in cancer clinical trials. PRO-CTCAE data will be collected and analyzed and reported separately from CTCAE AE data and will not be reconciled with each other. Adverse events for this study will be assessed, recorded, and reported in the standard manner with investigators using CTCAE.CCI
CCI
PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 44From the 78 symptomatic adve rse events, the following were selected to be ad ministered in 
the study , each with a 7 -day recall period : taste changes (S), decreased appetite (S and I), 
nausea (S and F), vomiting (S and F), fatigue (S and I) .
8.1.3.3. Patient’s Global Impression of Severity (PGI -S)
The Patient’s Global Impression of Severit y (PGI -S) (Appendix 10) is a single item measure 
that 
asks the study  participants to evaluate their current severity  of lack of appetite on a 
5-point verbal response scale that ranges from “None” to “Very  severe”.
The PGI -S is recommended by  Food and Drug Administration (FDA )for use as an anchor 
meas ure to generate an appropriate threshold that represents meaningful within -individual
change in the target patient popul atio
n. 
8.1.3.4. Patient’s Global Impression of Change (PGI -C)
The PGI -C (Appendix 1 1) is a 
single item measure that asks study  participants to rate the 
overall change in their level of appetite and fatigue since they  startedthe study  on a 7 -point 
verbal rating scales that ranges from “Much better” to “Much worse ”.  
The PGI -C is recommended by  FDA for use as an anchor measure to generate an appropriate 
threshold that represents meaningful within -individual change in the targ et patient 
population. 
8.1.3.5. PROMIS –Fatigue (ve rsion 7a)
The PROMI S Fatigue 7a 
(Appendix 12)is a self -reported measure that assesses a range of 
symptoms in the past 7 day s
from mild subjective feelings of tirednes s toan overwhelming, 
debilitating, and sustaine d sense of exhaustion that likely  decreases one’s ability  to execute 
daily  activities and function normally  in family  or social roles.
The short form 7A consists of 7 items that study  participants will rate f rom 1: “Never” to 5: 
“Alway s”.  A global raw scoreranging from 7 to 35 is calculate d and can be translated into a 
T-score (M ean= 50, standard deviation ( SD) = 10) using the applicable score conversion 
table provided in the PROMI S User’s Manual.
8.1.3.6. PROMIS –Phys ical Function (version 8c)
The PROMI S Phy sical Function short form 8C ( Appendix 13)is a self -reported 8 -item 
measure that assesses capability  rather than actual performance of ph ysical activities. It 
includes the functioning of one’s upper extremities (dext erity) and lower extremities 
(walking and mobility ), as well as instrumental activities of daily  living.  A single Phy sical 
Function capability  score is obtained from a short form.  A global raw score ranging from 
8to 40 is calculated and can be translate d into a T- score (Mean= 50, SD = 10 ) using the 
applicable score conversion table provided in the PROMI S User’s Manual.

PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 458.1.3.7. Functional Assessment of Anorexia-Cachexia Therapy (FAACT)
The Functional Assessment of Anorexia-Cachexia Therapy (FAACT) ( Appendix 14 )
measures combines the Functional Assessment of Cancer Therapy - General (FACT-G) core instrument and anorexia and cachexia subscale (ACS). 
FACT-G is a summated score of 27 items pertaining to physical well-being (7 items), 
emotional well-being (6 items), functional well-being (7 items), and social well-being (7 items) in the past 7 days. Each of the items uses a 5-point (0 to 4) scale. ACS is a 12-item summated scale containing items specific to patients’ perceptions of appetite and weight, alsousing the 5-point scale. Adding the 12 ACS items to the FACT-G produces the 39-item Functional Assessment of Anorexia-Cachexia Therapy (FAACT). Higher scores are associated with a higher health-related quality of life. For additional details regarding scoring refer to FACIT User’s Manual.
 
 
 
 
 
 
 
 
8.2. Safety Assessments
Planned time points for all safety assessments are provided in the SoA.  Unscheduled clinical 
laboratory measurements, imaging and other safety assessments may be obtained at any time during the study as part of standard of care or to assess any perceived safety concerns.
Injection site reactions will be assessed as part of standard safety/AE monitoring.  Additional 
assessments may be conducted at investigator discretion and/or until any symptoms resolve.  
Injection site reactions may include but are not limited to: erythema, induration, ecchymosis, 
pain, and pruritus.  The size and severity of injection site reactions will be assessed and documented.  If deemed appropriate by the investigator, a consultation with a dermatologist may be performed.  Documentation of a reaction may include items such as investigator notes, photographs, dermatologist report and/or clinic notes.CCI
PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 46In addition to the safet y monitoring as detailed in the SoA, safet y monitoring for th is 
open -label P hase 1b study  will include monthly  reviews of all available data to screen for 
trends in AEs, vital signs, ECGs and safet y laboratories.
8.2.1. Physical Examinations
Physical examinations may  be condu cted by a ph ysician, trained phy sician's assista nt, or 
nurse practitioner as accep table according to local regulation.
A fullphysical examination will include, at a minimum, head, ears, ey es, nose, mouth, skin, 
heart and lung examinations, ly mph nodes, an d gastrointestinal, musculosk eletal, and 
neurologi cal systems. and weight will also be measured and recorded , (height will be 
measured at screening only ).
An abbreviated physical examination will be focused on general appearance, the respiratory  
and cardiovasc ular s ystems, and subject -reported sy mptoms.
A full phy sical examination will be conducted at s creening onl y; Abbreviated phy sical exams 
planned at all other clinic visits, however full exams may  be performed for findings during 
previous exam, new/open AEs, or at investigator disc retion.
  Investigat ors should pay  special 
attention to clinical signs related to previous serious illnesses.
8.2.2. Eastern Cooperative Oncology Group (ECOG)
Assessment of ECOG performance status (see Appendix 16) may be cond ucted by  a 
physician, trained phy sician's assistant, or nurse practitioner as acceptable according to local 
regulation.
8.2.3. Vital Signs
Blood pressure and p ulse rate will be assessed at times spe cified in the SoA .
Blood pressure and 
pulse rate measurements w ill be assessed supine with a com pletely  
automated device. Manual techniques will be used only  if an automated device is not 
available. On Day  1, blood pressure and pulse ratewill be measured in t riplicate,
approximately  2 to 4 minutes apart.  The avera ge of the setriplicate measuremen ts collected 
prior to dosing on Day 1,will serve as each participant ’s baseline value. At all other visits, a 
single measurement will be colle cted.   Blood pressure and pulse rate measurements should be 
preceded b y at leas t 5 minutes of rest for the parti cipant in a quiet setting without distractions 
(eg, television, cell phones).
8.2.4. Electrocardiograms
Standard 12- Lead ECGs should be collected at ti mes specified in the SoA section of this
protocol . All scheduled ECGs should be perform ed after the participant has rested quietly  
for at least 10 minutes in a supine position. Participants should be in a quiet environment and 
not speak during the resting pe riod or measurement.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 47On Day  1, triplicate standard 12-lead ECGs will be obtained ap proximately 2 to 4 minutes 
apart.  The average of the triplicate ECG measurements collected prior to dosing on Day 1 
will se rve as each participant’s baseline value. At all other visits, a single standard 12-l ead
ECG wil l be collected. To ensure safet y of the participants, a qualified individual at the 
investigator site will make comparisons to baseline measurements.  Additional ECG 
monitoring will occur if a) an y postdose QTc interval is increased by  ≥60msec from the 
baseline and is >470 msec; or b) an absolute QTc value is ≥500 msec for any  scheduled 
ECG.  If either of these conditions occurs, then a single ECG measurement must be repeated 
at least hourl y until QTc value s from 2 successive ECGs fall below the threshold value that 
trigg ered the repeat measurement. In addition, if verified QTc values continue to exceed the 
criteria above, immediate correction for reversible causes including electrolyte abnormalities, 
hypox ia and concomitant medications for drugs with the potential to pro long the corrected 
QT (Fridericia method) (QTcF )interval should be performed.   A cardiologist should be 
consulted if QTc intervals do not return to less than the criterion listed above after 8 hours of 
monitoring (or sooner ,at the discretion of the inves tigator).
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality.  It is important that leads beplaced in t he 
same positions each time in order to achieve precise ECG record ings.  If a machine- read QTc 
value is prolonged, as defined above, repeat measurements may  not be necessary  if a 
qualified medical provider’s interpretation determines that the QTc value s are in the 
acceptable range.
ECG values of potential clinical concern arelisted in Appendix 7 .
8.2.5. Clinical Safety Laboratory Assessments
See Appendix 2 for the list of clinical safety laboratory  tests to be per formed and the SoA for 
the timing and frequency.
The investigator must review the laboratory  report, document this review, and record any  
clinically  relevant changes occurring during the study  in the AE section of the CRF. 
Clinicall y significant abnormal laboratory  findings are those which are not associated with 
the underl ying disease, unless judged by  the investigator to be more severe than expected for 
the participant's condition.
All laboratory  testswith values considered clinic ally significantl y abnormal during 
participation in the study  up to the time of the final planned follow -up visit after the last dose 
of study  intervention should be repeated until the values return to normal or baseline o r are 
no longer considered clinica lly significant by  the investigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by  
the investigator, the etiology  should be identified and the sponsor notif ied.
All protocol -required laborat ory assessments, as defined in Appendix 2 , must be conducted 
in accordance with the laboratory  manual and the SoA.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 48If laboratory  values from non -protocol -specif ied laboratory  assessments per formed at the 
institution’s local laboratory  require a change in participant management or are considered 
clinically  significant b y the investigator (eg, SAE or AE or dose modification), then the 
results must be recorded i n the CRF.
8.2.6. Pregnanc y Testing 
Pregnancy  tests may  be urine or serum tests, but must have a sensitivity  of at least 
25mIU/mL.  Pregnancy  tests will be performed in WOCBP at the times listed in the SoA .  
Urine pregnancy  tests will be provided by  the central lab . Fol lowing a negative pregnancy  
test result at screening, appropriate contraception must be commenced and a second negative 
pregnancy  test result will be required at the baseline visit prior to the participant ’sreceiving 
the PF -06946860.  Preg nancy  tests wi llalso be done whenever 1 menstrual cy cle is missed 
during the active treatment period (or when potential pregnancy  is otherwise suspected) and 
at the end of the stud y.  Pregnancy tests may also be repeated if requested by  institutional 
review boards (IRB s)/ethics committees (ECs) or if required by  local regulations.  I f a urine 
test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy  test is 
required.  In such cases, the participant must be excluded if 
the serum pregnancy  result i s 
positive.
8.3. Adverse Events and Serious Adverse Events
The definitions of an AE and an SAE can be found in Appendix 3 .
AEswill be reported b y the participant (or, when appropriate, b ya caregiver, surrogate, or 
theparticipant's legall y authorized representative). AEswill be assessed based on 
CTCAE 5.0.
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definiti
on of an AE or SAE and remain r esponsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether it 
meets the criteria for classification as an SAE or that caused the participant to discontinue the 
study (see Section 7).
In addition, the investigator may  be requested by  Pfizer Safet y to obtain specific follow -
up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for active ly eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed c onsent, 
which is obtained before the participant ’s participation in the study  (ie,before undergoing 
any study-related procedure and/or receiving investigational product), through and including 
a minimum of up to the time of the final planned follow-up visit, after the last administration 
of the investigational product.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 49Follow -up by theinvestigator continues throug hout and after the active collecti on period and 
until the event or its sequelae resolve or stabilize at a level acceptable to the investigator, and 
Pfizer c oncurs with that assessment.
For participants who are screen failu res,the active collection period ends when screen failure 
status is determined.
If the participant withdraws from the study and also withdraws consent for the collection of 
future informati on, the active collection period ends when consent is withdrawn.
If a participant definitively  discontinues or temporarily  discontinue s study  intervention 
because of an AE or SAE, the AE or SAE must be recorded on the CRF and the SAE 
reported using the CT SAE Report Form.
Investigators are not obligated to activel y seek AEsor SAE safter conclusion of the study  
participation.   However, i f the investigator learns of an y SAE, including a death, at an y time 
after a participant has been discharged from the stud y, and he/she considers the event to be 
reasonabl y related to the study intervention
, the investigator must promptl y report the SAE to 
Pfizer using the CT SAE Report Forms.
8.3.1.1. Reporting SAEs to Pfizer Safety
All SAEs o ccurring in a participant during the active collection period are reported to Pfizer 
Safety  on the CT SAE R eport Form immediatel y and under no circumstance should this 
exceed 24 hours, as indicated in Appendix 3 . The investigator will submit any  updated SAE 
data to the sponsor within 24 hours of it being available.
If aparticipant begins a new anticanc er therap y, SAEs occurring during the above- indicated 
active collection period must still be reported to Pfizer Saf ety irrespective of any  intervening 
treatment. Note that a switch to a commercially  available version of t he study intervention is 
considere d as a new anticancer therapy  for the purposes of SAE reporting.
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtai ning informed consent as described in Section 8.3.1 , will be recorded 
on the AE section of the CRF.
The investigator is to record on the CRF all directly  observed and all spontaneously  repor ted 
AEs and SAEs reported by  the p articipant.
If a participant begins a new anticancer therapy , the recording period for nonserious AEs 
ends at the time the new treatment is started; however, SAEs must continue to be recorded on 
the CRF during the above
-indicated active collection period. Note that a switch to a 
commerciall y ava ilable versi on of the stud y intervention is considered as a new anticancer 
therap y for the purposes of SAE reporting.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 508.3.2. Method of Detecting AEs and SAEs
The method of recording, evalu ating, and assessing causality of AEsand SAE sand the 
procedures for comp leting and transmitting SAE reports are provided in Appendix 3 .
Care will be taken not to introduce bias when detecting AEs and/or SAEs.   Open-ended and 
nonleading verbal que stioning of th e participant is the prefer red method to inquire about 
AEoccurrences.
8.3.3. Follow -
up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subseque nt visits/contacts. For each eve nt, the invest igator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow
-up (as defined in Section7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality .  An y informat ionrelevant to the event, such as conc omitant medications 
and illnesses, must be provided.  In the case of a participant death, a summary of available 
autopsy  findings must be submitted as soon as possible to Pfizer Safety . 
Further information on follow -up procedures is given in Appen dix 3 .
8.3.4.
Regulatory Reporting Requirements for SAEs
Prompt notification by  the investigator to the sponsor of a n SAE is essential so that legal 
obligations and ethic al responsibilities t owards the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation.  The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, institutional review boards (IRB s)/ethics committees 
(ECs), and i nvestigators.
Investi gator safety  reports must be prepa red for suspected unexpected serious adverse 
reactions (SUSAR s) according to local regulatory
 requirements and sponsor policy  and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing a nSAE or other
specific safet
y information (eg, summary or listing of SAEs) from the sponsor will review 
and then file it along with the investigator’s brochure and will notify  the IRB/EC, if 
appropriate according t o local requirements.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 518.3.5. Exposure During Pregnancy or Breastfee ding, and Occupational Exposure
Exposure to the investigational product under study  during pregnancy  or breastfeeding and 
occupational exposure are reportable to Pfizer Safety  within 24 hours of i nvestigator 
awareness .
8.3.5.1. Exposure During Pregnancy
Detail s of 
all pregnancies in female participants and, if indicated, female partners of male 
participants will be collected after the start of study intervention and until approximately  
130daysthat is at least 5 terminal half -lives after the last dose.
If a pr egnan cy is reported, the investigator should inform the sponsor within 24 hours of 
learning of the pregnancy  and should follow the procedures outlined in Appendix 4 .
Abnormal pre gnancy  outcomes (eg, spontaneou s abo rtion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy ) are considered SAEs.
8.3.5.2. Exposure During Breastfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to Pfizer Safet y wit hin 24 hours of the investigator’s awareness, using the 
CT SAE Report Form.  An exposure during breastfeeding report is not created when a Pfizer 
drug specifically  approved for use in breastfeeding women (eg, vitamins ) isadministered in 
accord with a uthor ized use.  However, if the infant experiences an SAE associated with such 
a drug’s administration, the SAE is reported together with the exposure during breastfeeding.
8.3.5.3. Occupational Exp osure
An occupational exposure oc curs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact with the 
product, which may  or may  not lead to the occurrence of an AE.
An occupati onal exposure is reported to Pfiz er Safety  within 24 hours of the i nvest igator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the information does not pertain to a participant enrolled in the study , the 
information is not recorded on a CRF ;however, a copy  of the comple ted C T SAE Report 
Form is maintained in the investigator site file .
8.3.6. Cardiovascular and Death Events
Not applicable .
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 528.3.8. Adver se Events of Special Interest
All AESI s must be reported as an AE or SAE following the procedures described in 
Sections 8.3.1 through 8.3.4 .  An AESI  is to be recorde d asan AE or SAE on the CRF.  In 
addition, an AESI  that is also an SAE must be reported using the CT SAE Report Form.
8.3.8.1. Lack of Efficacy
Lack of efficacy  is reportable to Pfizer Safet y only if associated with an SAE.
8.3.9. Medical Device Deficienc ies
Not applicable .
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the investigational 
product b y the wrong participant, or at the wrong time, or at the wrong dosage strength .
Exposures to the investigational pro duct under study may occur in clinical trial settings, such 
as medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form to Pfizer Safety Within 
24 Hours of Awareness
Medication errors All (regardless of whether 
associated wi th an AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the investigational product;
Potential medication errors or uses outside of what is foreseen in th eprotocol that do 
or do not involve the study partic ipant.
Such medication errors occurring to a study participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours .
Whether or not the medication error is accompanied by  an AE, as determined by  the 
investigator, the medication error is r ecorded on the medication error page of the CRF and, if 
applicable, an y associat ed AE(s), serious and nons erious, are recorded on an AE p age of the 
CRF.
Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report 
Form only wh en associated with an SAE .

PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 538.4. Treatment of Overdose
Based on preliminary population PK/PD simulations, doses greater than approximately
11,000 mg, administered when exposure is expected to be at steady state, are projected toresult in exposure exceeding the NOAEL from the 6-month toxicology study in monkeys(Section 2.2.3 ). The definition of overdose for this trial is based on the operational aspects of 
the protocol design. Given the nature of this study (ie, subcutaneous dose administered in the clinic), and the allowed visit window, an overdose will be defined as more than 2 doses of PF-06946860  SC administered in a period of 3 weeks.
There is no specific treatment for an overdose of PF-06946860, and the sponsor recommends 
general supportive medical care as clinically indicated.
In the event of an overdose, the investigator should:
1. Contact the medical monitor immediately.2. Closely monitor the participant for any AEs/SAEs and laboratory abnormalities for at 
least 5 half-lives or 28 calendar days after the overdose of PF-06946860 (whichever is longer).  The duration of monitoring required will be provided by the sponsor.
3. Obtain blood samples for PK, PD and/or immunogenicity analysis approximately 
5-7 days from the date of the last dose of study intervention if requested by the medical monitor (determined on a case-by-case basis).
4. Document the quantity of the excess dose as well as the duration of the overdose in 
the CRF.
5. Overdose is reportable to Safety only when associated with an SAE.
Decisions regarding dose interruptions or modifications will be made by the investigator in
consultation with the medical monitor based on the clinical evaluation of the participant.
8.5. Pharmacokinetics 
Blood for PK samples will be drawn from the arm contralateral to any drug infusion.
Blood samples of approximately 6 mL, to provide a minimum of 2 mL serum, will be 
collected for measurement of serum unbound and total concentrations of PF-06946860, as specified in the SoA.  Instructions for the collection and handling of biological samples will 
be provided in the laboratory manual or by the sponsor. The actual times may change; theactual date and time (24-hour clock time) of each sample will be recorded.
All efforts will be made to obtain the samples at the exact nominal time relative to dosing.  
Collection of samples within the protocol-allowed visit window (±1, ±3, ±7 days, as defined in the SoA) will not be captured as protocol deviation, as long as the exact time of the 
collection is noted on the source document and the CRF. CCI
PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 54The blood sampling to be conducted during the at home visits (per SoA) is intended to be 
done at home b y a visiting health care professional for the participant’s convenience, but 
blood sampling ma y be conducted at the clinic, at the discretion of th e participant or 
invest igator
Samples will be used to evaluate the PK of PF -06946860. Samples collected for anal ysis of 
PF-06946860 serum con centration may also be used to evaluate safet y or efficacy  aspects 
related to concerns arising during ,or after , the study, for metabolite identification and/or 
evaluation of bioanal ytical methods, or for other inter nal exploratory  purposes.  Any  such 
data generated may not be included in the CSR.
Genetic anal yses will not be performed on PK samples unless consent for this was included 
in the informed consent.  Participant confidentiality will be maintained.
Samples collected fo r measurement of serum unbound and total concentrations of 
PF-06946860 will be analy zed us ing validated analy tical methods in compliance with 
applicable SOPs.
The PK samples must be processed and shipped as ind icated in the instructions provided to 
the investi gator site to maintain sample integrity .  Any deviations from the PK sample 
handling p
rocedure (eg, sample collection and processing steps, interim storage or shipping 
conditions), including any actions tak en, must be documented and reported to the sponsor .  
On a case -by-case basis, the sponsor may  make a determination as to whether sample 
integrit y has been compromised.
8.6.Pharmacodynamics of GDF-15 
Blood 
sampl es of approximately 6mL, to provide a minimum of 2 mL  serum , will be 
collected for measurement of 
serum concentrations of total GDF -15, and if feasibl e, unbound 
GDF -
15at time points specif ied in the SoA . 
Instruc tions for the collection and handling of biological samples will be provided in the 
laboratory manual or by  the sponsor. The actual times may  chan ge;the actual date and time 
(24-hour clock time) of eac h sample will be r ecorded.
All efforts will be made t o obtain the samples a t the exact nominal time relative to dosing.  
Collection of samples within the protocol -allowed visit window (±1, ±3, ±7 day s, as defined 
in the SoA ) will n ot be captured as protocol deviation, as long as the exact time of the 
collection is noted on the source document and the CRF.  
The blood sampling to be conducted during the at home visits (per SoA) is intended to be 
done at home by  a visiting health care professional for the partic ipant’s convenience, but 
blood sampling may  be conducted at the clinic, at the discretion of the participant or 
investigator.
As part of understanding the PD of the study  intervention, samples may  be u sed for 
evaluation of the bioanalyti cal method , as we ll as for other internal exploratory  purposes.  

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 55At screening, 2 GDF -15 samples will be collected. One GDF- 15 sample will be analy zed 
using the IUO Roche Elecsy s GDF -15 a ssay, for determination of enrol lmen t eligibility . 
This assay will be validated in a CLIAaccredited central laboratory . The second screening 
sample will be anal yzed using the inte rnal Pfizer GDF -15 assay (s). 
All s erum PD samples will be anal yzed for total GDF -15 and ,if feasible, unbound GDF-15, 
using validated anal ytical met hods in compliance with applicable SOPs.
PD s amples collected in this study  may also be analy zed using the Roche assay  and/or a 
fit-for-
purpose validated anal ytical method incompliance with applicable SOPs. These data 
may be included in the CSR, if deeme d appropr iate. 
The PDsamples must be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity .  Any  deviations from the PD sample 
handling procedure (eg, sample collection and processing steps, interim stor age,or shipping 
conditions), including any actions taken, must be documented and reported to the sponsor.  
On a case -by-case basis, the sponsor may  make a determination as to w hether sampl e 
integrit y has been compromised.
8.7.Genetics
8.7.1. Specified Genetics
Genetics (specified anal yses) are not evaluated in this study .
8.7.2. Banked Biospecimens for Genetics
A 4-mLblood sample optimized for deox yribonucleic acid ( DNA )isolation Prep D1 will be 
collected as local r egulations and I RBs/ECs al low.
Banked biospecimens m ay be used for research related to drug response andcachexia .  
Genes and other analy tes (eg ,proteins, ribonucleic acid (RNA ), nondrug metabolites) may  be 
studied usi ng the banked samples. 
Unless prohi bited by  local regulations
or IRB/EC decision, participant s will be asked to 
indicate on the consent document whether they  will allow their banked biospecimens to also 
be used to design and conduct research in order to g ain a further understanding of other
diseases and to advance s cience, including developme nt of other medicines for patients.  This 
component of the sampling banking is optional for participants; they  may  still participate in 
the study  even if they  do not a gree to the additional research on t heir banked biospecimens . 
The optional additional re search does not require the collection of an y further samples.
See Appendix 5for information regarding genetic research.
  Details on processes for 
collection a nd shipment of these samples can be found in the labo ratory manual .
8.8.Biomarkers
There are no additional biomarkers plann ed for this study  aside from GDF -15.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 568.8.1. Banked Bi ospecimens for Biomarkers
A 10-mLwhole bloo d sample for seru m(Prep B2 )and a 6 -mL whole blood sample for 
plasma (Prep B1.5) will be collected as local regulations and IRB/ECs allow.
Banked biospecimens may be used for research related to drug response and cachexia .  
Genes and other analy tes (eg ,proteins, RNA, nondrug metaboli tes) may  be studied using the 
banked samples. 
Unless prohib
itedby local regulations or IRB/EC decision, participant s will be asked to 
indicate on the consent document whether they  will allow their banked samples to also be 
used to design and conduct rese arch in order to gain a further unde rstanding of othe r disea ses 
and to advance science, including development of other medicines for patients.  This 
component of the sampling banking is optional for participant s; they  may  still participate in 
the study  even if they  do not agree to the additi onal research on their b anke d samples.  The 
optional additional research d oes not require the collection of any  further samples.
See Appendix 5for information regarding genetic research. Details on processes for 
collection and sh ipment of these sampl es can be found in the laboratory  manual. 
8.9.Immunogenicit y Assessments
Blood samples of approximately  6mL, to provide a minimum of 2 mL of serum , will be 
collected for determi nation of ADA and NAb as specified in the SoA.  Instruct ions for the 
collection and handling of biological samples will be provided in the labor atory  manual or by  
the sponsor.  Theactual date and time (24 -hour clock time) of each sample will be recorded. 
Samples collected for determination of AD A an d NAb may  also be used for additional 
characte rization of the immune response , to eva luate safety  or efficacy  aspects related to
concerns arising during or after the study ,and/or evaluation of the bioanal ytical method, or 
for other internal explorator y purposes. These data will be used for internal exploratory  
purposes and may  not be included in the CSR.
Genetic anal yses will not be performed on these serum samples 
unless consent for this was 
included in the informed consent. Participant confi dential ity will be ma intained.
Samples will be analy zed u sing a validated anal ytical method in c ompliance with applicable 
SOPs. Samples determined to be positive for ADA may be further characterized for NAb.
The immunogenicit y samples must be processed an
d shipped a s indicate d in the instructions 
provided to th e investigator site to maintain sample integrity .  An y deviations from the 
immunogenicit y sample handling procedure (eg, sample collection and processing steps, 
interim storage ,or shipping condition s), inc luding any  actions taken, must be documented 
and r eported to the sponsor.   On a case -by- case basis, the sponsor may  make a determination 
as to whether sample integrit y has been compromised.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 578.10. Health Economics
Health e conomics/ medical resource utilization and health econom icsparameters are not 
evaluated in 
this study .
9.STATISTICAL CONSIDERATIONS
Detailed methodology  for summary  and statistical anal yses of the data collected in this study  
is outlined here and further detailed in a statistical anal ysis plan (SAP ), which will be 
maintained by  the sponsor.  The S APmay modify  what is outlined in the protocol where 
appropriate; however, any  major modifications of the primary  endpoint definitions or their 
analyses will also be ref lected in a protocol amendment .
9.1.Estim ands and Stati stical Hypotheses
There are no stati stical hy potheses or estimands for thi s study .
9.2.Sample Size Determination
A sample size of approximately  6participants per cohort has been chosen based on the need 
to minimize first exposure to patie nts of a ne w chemical entity  and the requirement to 
provi deadequate safet y
, tolerability and P K/PD assessment.  Approximately  8participants
will be assigned to the investigational product such that approximately  6evaluable 
participants complete the study, per coho rt. 
The additional second cohort ma y be included if needed to meet stud y objectives, as 
informed b y data emerging from this study.
Participants who discontinue prior to completion of the study  may  be replaced, at the 
discretion of the sponsor.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 589.3.Populat ions for Analysis
For purposes of analy sis, the following populations are de fined:
Population Description
Enrolled /Randomly  
assigned to 
investigational product"Enrolled" means a participant's, or their legall y authorized 
representative’s, agreement to participate in a clinical study  
following completion of the informed consent process.  
Potential participants who are screened for the purpose of 
determining eligibility  for the study , but do not participate in 
the study , are not considered enrolled, unles s otherwise 
specified b y the protocol
Evaluable Allparticipants randomly  assigned t o investigational product 
and who ta ke at least 1 dose of investigational product
Safety All participants randomly  assigned to investigational product
and who take a t least 1 dose of investigational product
PK All randomi zed participants who received a d ose of 
PF-06946860 and in whom at le ast 1 serum concentration 
value is reported
PD All randomized participants who received a dose of 
PF-06946860 and in whom at least 1 ser um G DF-15 
conc entration is reported
Immunogenicit y All randomized participants who received a dose of 
PF-06946860 and in whom at least 1 ADA result is reported 
Efficacy All participants randomly  assigned to investigational product 
and who take at least 1 do se of inve stigational product
9.4. Statistical Ana lyses
The SAPwill be developed and finalized be fore database lock and will describe the 
participant populations to be included in the analy ses, and procedures for accounting for 
missing, unused, and spurio us data.   This section is a summary  of the planned statistical
analyses of the primary  and seconda ry endpoints. Details of the analy sis of all 
exploratory /tertiary  endpoints will be described in the SAP.
9.4.1. Efficacy Analyses
Analy ses of the explorator y efficacy assessment s defined in Section 8.1 will be described in 
the SAP. These anal yses will be performed on the efficacy  population.
9.4.2. Safety Analyses
All safet y anal yses will be performed o
n the s afety population.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 59AEs, ECGs, blood pressure (BP), pulse rate and safety  laboratory data will be reviewed and 
summarized on an ongoing basis during the stud y to evaluate the safet y ofparticipants. Any 
clinical laboratory , ECG, BP, and pulse rate ab normali tiesof potent ialclinical concern will 
be describ ed.  Safety data will be present ed in tabular and/or graphical format and 
summarized descriptively, where appropriate.
Medical history  and phy sical examination, collected during the course of the stu dy, will be
considere d source data and will not be re quired to be reported, unless otherw ise noted. 
However, an y untoward findings identified on ph ysical and/or neurological e xaminations 
conducted during the active collection period will be captured as AE s, if t hose findings meet 
the definition of an AE. 
9.4.2.1. Elect rocardiogram Analyses
Changes from baseline for the ECG parameters QT interval, heart rate, QTc interval , PR 
interval, and QRS complex will be summarized by time (and cohort, if applicable).
The number (%) of participant s with maximum postdose QTc values a nd maximum increases 
from baseline in the following categories will be tabulated (by cohort, if applicab le): 
Safety QTc Assessment
Degree of Prolongation Mild (msec) Moderate (msec) Severe (m sec)
Absolu te value >470-480 >480-500 >500
Increase from baseline 30-60 >60
In addition, the number of participant s with uncorrected QT values >500 msecwill be 
summarized.
9.4.3. Pharmacokinetic Analyses
All PK analy ses will be performed on the PK population.
Theserum conc entration of unbound and total PF-06946860 wil l bepresented in tabular 
and/or graphical format and summarized descriptively , where appropriate. Serum unbound 
and total Ctrough will be summarized by time (and cohort, if applicable).  No formal inferential
statistic s will be applied to the pharmacokin eticdata.   Details of planned analy ses will be 
given in the SAP.
Additional PK ,or population PK analy ses may  be performed if deemed 
appropriate, and will 
not be included in the CSR.

PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 609.4.4. Other Analyses 
Demographic data, GDF-15 concentration, height, weight, CT scan, ECOG, 
, PROs (Cohort 1) and AEs, collected at screening, may be reported.  Other data 
collected at screening, that are used for inclusion/exclusion criteria, such as laboratory data, ECGs and vital signs, will be considered source data, and will not be required to be reported, unless otherwise noted.
9.4.4.1. Pharmacodynamic Analyses
All PD analyses will be performed on the PD population. 
The serum concentration of total GDF-15 and, if feasible, unbound GDF-15, will be 
presented in tabular and/or graphical format and summarized descriptively, where appropriate.  Details of planned analyses will be given in the SAP.
Additional PD, and/or population PK/PD, analyses may be performed if deemed appropriate, 
and will not be included in the CSR.
9.4.4.2. Immunogenicity Analyses
Immunogenicity analyses will be pe rformed on the Immunogenicity population.
Incidence of ADA and NAb, if applicable, will be summarized. The number of 
ADA-positive and NAb-positive participants will be summarized by time, if appropriate. Potential impact of ADA and/or NAb on PK, PD and safety may be assessed, if appropriate.  Details of planned analyses will be given in the SAP.
9.5. Interim Analyses
As this is an open-label study, the sponsor may  conduct unblinded reviews of the data during 
the course of the study for the purpose of safety assessment, facilitating PK/PD modelling, and/or supporting clinical development.
A formal interim analysis may be performed to as sess PK, PD and/or safety. Interim analysis 
results may be used for internal business decisions regarding future study planning. If a formal interim analysis is conducted, details of the timing, objectives, decision criteria (if applicable) and analyses will be documented in an internal charter or in the final SAP.
9.5.1. Data Monitoring Committee 
This study will not use a data monitoring committee (DMC).CCI
PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 6110. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Conside rations
10.1.1. Regulatory and Ethic al Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council 
for Inte rnational Organizations of Medical 
Sciences (CIOMS ) International Ethical Guidelines;
Applicable International Council for Harmonisation (I CH) Good Clinical Practice 
(GCP) guidelines;
Applicable laws and regulations, including applicable p rivacy  laws.
The protocol, prot ocol amendment s, ICD, investigator’s brochure (IB), and other relevant 
documents (eg, advertisements) must be reviewed and approved by  the sponsor and 
submitted to an I RB/EC by  the investigator and reviewed and approved b y the IRB/EC 
before t he study is in itiated.
Any amendments to the proto col will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
The investigator will
be responsi ble for th e following:
Providing written summa ries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  the IRB/EC;
Notify ing the IRB/ EC of SAEs or othe r signi ficant safet y findings as re quired by  
IRB/EC proce dures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 Code of Federal Regulations (CFR), I CH guidelines, the I RB/EC, 
European regula tion 536/2014 for clinica l studies (if applicable), a nd all other 
applicabl e local regulations.
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed ( ie,clinical hold) b y an ap plicable 
regulatory  authori ty in any  area of the worl d, or if the investigato r is aware of any  new 
information that might influence the evaluation of the benefits and risks of the investigational 
product, Pfizer should be informed immediately
. 

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 62In addition, the investigato r will inf orm Pfizer imm ediately  of any urgent safet y measur es 
taken b y the investigator to protect the study participants against an y immediate hazard, and 
of an y serious breaches of this protocol or of ICH GCP that the investigator becom es aware 
of.
10.1.2. Fina ncial Disc losure
Investi gators and s ubinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropria te 
regulat ory authoritie s.  Investig ators 
are responsible fo
r providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her re presentative will explain t he nature of t he study  to the 
participant or his/h er legally  authorized representative and answer all questions regarding the 
study .
Participants must be informed that their participation is voluntary .  Participants or their 
legally authorized re presentati ve w ill be req uired to sig n a statement of informe d consent that 
meets the requirements of 21 CFR 50, local regulations, I CH guidelines, Health I nsurance 
Portability  and Accountability  Act (HIPAA) requirements, where applicable, and the IRB/EC 
orstudy center.
The inves tigator must ensure that each study  participant or his or her legally  authorized 
representative is fully  informed about the nature and objectives of the study , the sharing of 
data related to the study , and possible risks associated 
with parti cipation, incl uding the ri sks 
associated with the processing of the participant’s personal data. 
The participant must be informed that his/her personal study -related data will be used by  the 
sponsor in accordance with local data protection law. The level of disclosure must also b e 
explained to the parti cipant.
The participant must be informed that his/her medical records may  be examined by  Clinical 
Quality  Assurance auditors or other authorized personnel appointed by  the sponsor , by 
appropriate IRB/EC mem bers, and b y inspectors fr om regulatory  authoritie s.
The investigator further must ensure that each study  participant or his or her legall y 
authorized representative isfully  informed about his or her right to access and correct his or 
her person al data and to withdraw consent for the processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date the writte n consent was obt ained.  
The authorized person obtaining the informed consent must also sign the ICD.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 63Participants must be reconsented to the most current version of the ICD(s) during their 
participation in the study .
A cop y of the ICD(s) must be provided to the participant o r the parti cipant’s legall y 
authorized representative.
The ICD will contain a separate section that addresses the use of remaining mandatory  
samples for optional exploratory  research. The investigator or authorized designee will 
explai n to each partici pant the o bjectives of t he explorato ry research. Participan ts will be 
told that they  are free to refuse to participate and may  withdraw their consent at any  time and 
for an y reason during the storage period. A separate signature will be required to docum enta 
particip
ant's agre ement to all ow an y remaining specime ns to be used for exploratory  
research. Participants who decline to participate in this optional research will not provide 
this separate signature.
10.1.4. Data Protection
All parties will comply  with al l applicable l aws, including laws re garding the implementati on 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electroni c and/or paper 
form and wil l be passw ord protected or secured i n a locked room to ensur e that only  
authorized study  staff have access.  The study  site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster.  In the event of a potentia l personal data breach, the study  site shall be responsible 
for determining whether a personal data breach has in fact occurred and, if so, providing 
breach notifications as required by  law.
Toprotect the rights and fre edoms of n atural persons with regard to the processing of 
personal data, participants will be assigned a single, participant -specific numerical code.  
Any participant records or data sets that are transferred to the sponsor will contain the 
numerical code; pa
rticipa nt names will not be trans ferred.  All other identifiable data 
transferred to the sponsor will be identified by  this single, participant -specific code.  The 
study  site will maintain a confidential list of participants who participated in the stud y, 
linking each particip ant’s numeri cal code to his or her a ctual identity .  In case of data 
transfer, the sponsor will protect the confidentiality of participants’ personal data consistent 
with the clinical study  agreement and a pplicable privacy  laws.
10.1.5. Dis semination of Clinical S tudy Data
Pfizer fulfills its commit ment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Trials 
Database (EudraCT), and/or www.pfi zer.com , and other pu blic registr ies in accordance with 
applicable local laws/regulations.  I n addition, Pfizer reports study  results outside of the 
requirements of local laws/regulations pursuant to its standard op erating procedures (SOPs).

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 64In all case s, study  results are reported b y Pfi zer in an objective, acc urate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.
www.clinicaltria ls.gov
Pfizer posts clinical trial US Bas ic Results on www.cli nicaltrials. gov for Pfizer- sponsored
interventional studies (conducted in patients) that evaluate the safet y and/or efficacy of a 
product, regardless of the geographical location in which the st udy is conducted.  US Basic 
Results ar e generall y submitted fo r posting wi thin 1 year of the prima ry completion date 
(PCD) for studies in adult populations or within 6 months of the PCD for studies in pediatric 
populations.
PCD is defined as the date that the final participant was examined or received an in tervention
for the pur poses of final collection of data for the primary  outcome, whether the clinical 
study  concluded according to the prespecified protocol or was terminated.
EudraCT
Pfizer posts Europea n Union (EU) Basic Results on EudraCT forall Pf izer-sponsored
interventio nal studies that are in scope of EU requirements.  EU Basic Results are submitted 
for posting within 1 year of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric populations.
www.pfizer .com
Pfizer posts public disclosure s ynopses (CSR synopses in which any  data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
Pfizer -sponsored interventional stu dies at the same time the US Basic Res ults document is 
posted to www.clinicaltrials.gov.
Documents within marketing authorization packages/submissions
Pfizer complies with the European Union Policy  0070, the proactive publication of clinical 
data to the Eu ropean Medicines Agency  (EMA) website.   Clinical data, under P hase 1 of th is 
policy , includes clinical overviews, clinical summaries, CSRs, and appendices containing the 
protocol and protocol amendments, sample CRFs, and statistical methods.  Clinical data , 
under Phase 2 of this policy , includ es the publish ing of individual part icipant data.  
Policy 0070 applies to new marketing authorization applications submitted via the 
centralized procedure since 01 January 2015 and applications for line extensions and for new 
indications submitted via the centralize d procedure si nce 01 July  2015.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 65Data Sharing
Pfize r provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute to the scientific understanding of the 
disease, target, or compoun d class.  Pfiz er will make available data from the se trials 
24months after study  completion.  Patient -level data will be anon ymized in accordance with 
applicable privacy  laws and regulations.  CSRs will have personall y identifiable information 
redacted.
Data requests a re considere d from qualified researc hers with the appropriate competencies to 
perform the proposed analyses.  Research teams must include a biostatistician.  Data will not 
be provided to applica nts with significant conflicts of inte rest, incl uding individu als 
requesti ng access for commercial/competitive or legal purposes.
10.1.6. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmi tted to the sponsor or designee electroni cally  (eg, laboratory data).  The investigator is 
respons ible for verify ing that data entries are accurate and correct by  physically  or 
electronically  signing the CRF.
The investigator must maintain accurate documen tation (source data) that supports the
informati on entered in the CRF.
Theinvestigator must ensur e that the CRFs are securel y stored at the study site in encrypted 
electronic and/or paper form and are password protected or secured in a locked room to 
prevent access by unauthorized third parties.
The invest igator must permit stu dy-related monitoring, a udits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents.  This 
verification may  also occur after study  comp letion.  I t is important that the inve stigator(s ) 
and their re levant personnel are available durin g the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy  (eg, ris k-based initiatives in operations and quality 
such as risk management and mitigation strategies an d anal ytical risk- based monitoring), 
methods, responsibilities, and requirements, including handling of noncompliance issues and 
monitoring techniques (centra l, remote, or on -site monitoring), are provided in the study  
monitoring pl an(SMP) .
The sponsor or designee is responsible for the data management of this study , including 
quality  checking of the data.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 66Study  monitors will perform ongoing source data verifi cation to confirm that data entered 
into the CRF by authorized site person nel are accurate, comple te, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol a nd any  other study 
agree ments, I CH G CP, and all applicable r egulatory  requirements.
Records and documents, including signed ICDs, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local 
regulation s or
institutional policie s require a longer reten tion period.  No records may  be destroy ed during 
the retention period without the written approval of the sponsor.  No records may  be 
transferred to another location or party without written notif ication to the sponsor. The 
investi gator must ensure that t he records continue to be stored securel y for as long as they are 
maintained.
When participant data are to be deleted, the investigator will ensure that all c opies of such 
data are promptly  and ir revocabl y deleted from a ll systems.
The investigator(s) will notify  the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study .  Furthermore, the investigator will cooperat e 
with the sponsor or its agents to pr epare the inve stigator s ite for the inspection and will allo w 
the sponsor or its agent, whenever feasible, to be present during the inspection.  The 
investigator site and investigator will promptly  resolve any  discrepa ncies that are identified 
between the stu dy data andthe parti cipant's med ical records.  The inves tigator will promptly  
provide copies of the inspection findings to the sponsor or its agent.  Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agent s with an opportunity  to review and comment on responses to an y such findings.
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the dat a collected.  Source documents are fil ed at the investigator s
ite.
Data re ported on the CRF or ent ered in the electronic CRF (eCRF) that are transcribed from 
source documents must be consistent with the source documents or the discrepancies must be 
explained.  The investigator may  need to requ estprevio us m edical rec ords or transfer 
records, depending on the study .  Also, current medical records must be available.
Definition of what constitutes source data can be found in 
the SMP.
10.1.8. Study and Site Clos ure
The sponsor designee reserves the right to c lose th e study site or terminate the study  at any  
time fo r any reason at the sole discretion of the sponsor.  Study  sites will be closed upon 
study  completion.  A study  site is considered closed when all requ ired documents and study  
supplies have been c ollected a nd a study -site closure vi sit has been performed.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 67The investigator may  initiate study -site closure at any  time upon notification to the contract 
research organization (CRO) if requested to do so by  theresponsible IRB/EC or if such 
termination is required to p rotect the health of study  participants.
Reaso ns for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authoritie s, the sponsor 's procedure s, or GCP guidelines;
Inadequate recruitment of participants by  the investigator;
Discontinuation of further study  intervention development.
Study  termination is also provided for in the clinical study agreement.  If the re is an y conflict 
betwe en the contr act and this protocol, t he contract will control as to termination rights.
10.1.9. Publication Policy
The results of this study  may  be published or presented at scientific meetings b ythe 
investigator after publication of the ov erall stud y results or 1 year after end of the study (or 
study termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subsequent publications 
such as secondary  manuscripts, and submits all manuscripts or ab stracts to thesponsor 
30days befor e submission.  This allo ws the sponsor to protect proprietary  information and to 
provide comments and the investigator will, on request, remove an y previously  undisclosed 
confidential information before disclosure, excep t for an y study
- or Pfiz er 
intervent ion-related information necessary  for the appropriate scientific presentation or 
understanding of the study  results.
For all publications relating to the stud y, the investigat or will compl y with recognized ethical 
standa rdsconcer ning publications and authorship, including those established by  the 
International Committee of Medical Journal Editors.
The sponsor will comply  with the requirements for publication of the overall study  results 
covering all investigator sites.  In accorda nce with stand ard editoria l and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data.  I n this case, a coordinating inves tigator will be designated b y mutual 
agreement.
Authors hip of publica tions for the overall study  results will be determined by  mutual 
agreement and in line with I nternational Committee of Medical Journal Editors authorship 
requirements. 
If publication is addressed in the clinical study  agreement, th e publicat ion policy  setout in 
thissection will not apply.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 6810.1.10. Sponsor’s Qualified Medical Personnel
The contact information for the sponsor's appropriately qualified medical personnel for the 
study  is documented in the study  contact list located in the stud y team on demand (SToD) 
system.  
Tofacilitate access to ap propriatel y qualified medical personnel on stud y-related medical 
questions or problems, participants are provided with a contact card.  The contact car d 
contains, at a minimum, protocol and invest igational product identifiers, parti cipant numbers, 
contact information for the investigator site, and contact details for a contact center in the 
event that the investigator site staff cannot be reached to prov ide advice on a medical 
question or problem o riginating from another healthcare professional not involved in the 
participant’s participation in the study .  The contact number can also be used by  investigator 
staff if they  are seeking advice on medical questions or problems; however, it should be used
only in the event that the establis hed communication pathwa ys between the investigator site 
and the study  team are not available.  It is therefore intended to augment, but not replace, the 
established communica tion pathway s between the investigator site and the stu dy team for 
advice on medi cal questions or problems that may arise during the study .  The contact 
number is not intended for use b y the participant directly, and if a participant calls that 
number, he 
or she will be directed back to the investiga torsite.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 6910.2. Appe ndix 2: Cl inical Labor atory Tests
The followin g safet y laboratory  tests will be performed at times defined in the SoA section of 
this protocol.  Additional laboratory  results may  be reported on these samples as a resul t of 
the m ethod of anal ysis or the t ype of anal yzer used by  the clinical laboratory ; or as derived 
from calculated values.  These additional tests would no t require additional collection of 
blood.  Unscheduled clinical laboratory  measurements may  be obtain ed at any  time during 
the study  to assess any  perceived safe ty concerns.
Table 3. Protocol -Required Safety Laboratory Assessments
Hem atology Chemistry Urinalysis Other
Hem oglobin
Hem atocrit
RBC count
MCV
MCH
MCHC
Platelet count
WBC c ount
Total neutrophils ( Abs)
Eosinop hils (Abs)
Monocytes (Ab s)
Basophils (Abs)
Lymphocytes (Abs)BUN/urea and Creatininea
Glucose 
Calcium
Sodium
Potassium
Chloride
Total CO 2(bicarbonate)
AST, ALT
Total bilirubin
Alkaline phosphatase
Uric acid
CRP
Pre-albumin
Album in
Total prote inpH
Glucos e (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esterase
Urobilinogen
Urine bilirubin
MicroscopybPregnancy test ( -hCG)c
At screening only:
FSHd
Hepatitis B surface antigen
Hepatitis C antibody
HIV
Abbrev iations: Abs = absolu te; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
-hCG = beta -human chorionic gonadotropin; BUN = blood urea nitrogen; CO 2 = carbon dioxide;
CRP = C-reactive protein ; FSH =follicle -stimulating hormone; MCH = mean corpus cularhemoglobi n; 
MCHC = mean corpuscular hemoglobi n concentration; MCV = mean corpuscular volume; 
MDRD =Modification of diet in renal disease; pH = pow er of hydrogen; qual = qualitative; RBC =red blood 
cell; WBC = wh ite blood cell. 
a.Glom erular F iltrat ion R ate (GFR) will be calculated using the modific ation of diet in renal disease 
(MDRD) equation.
b. Only if urine dipstick is positive for blood, protein, nitrites, or leukocyte esterase.
c. Local urine testing will be standard for the protocol unl ess se rum testing is required by local regulation or 
institutional review board/ethics committee (IRB/EC).  Serum or urine -hCG for female participants of 
childbearing potential.
d. For confirmation of postmenopau sal status only.
Investigators must docu ment th eir review of each laboratory  safet y report.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 7010.3. Appen dix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE i s any untoward medical occurrence in a patient or clinical study  
participant, t emporall y associated with the use of study  intervention, whether or not 
considered related to the study  intervention.
NOTE: An AE can ther efore be an y unfavorable and unintended sign (including an 
abnormal laborat ory finding), s ymptom, or dis ease (new or e xacerbated) temporally  
associated wi th the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assess ments (eg, ECG, radiol ogical scans, vital s ign measurements), 
including those t hat worsen from baseline, considered clinicall y significant in the 
medical and scie ntific judgment of the investigator (ie , not related to progression of 
underly ing disease).
Exacerbation of a chroni c or interm ittent pre existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detect ed or diagnosed after study  intervention administration ev en 
though it may  have been present b efore the start of the study .
Signs, symptoms , or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspe cted overdose of either study  
intervention or a concomitan t medication.  Overdose per se will not be reported as 
an AE
/SAE unless it is an intentional overdose taken with possible 
suicidal/self
-harming intent.  Such overdoses should be reported regardless of 
sequel ae.
Events NOT Meeting the AE Definition
Any clinically  significant abnormal labor atory  findings or other abnorma l safety 
asses sments which are associated with the underl ying disease, unless judged by  the 
investigator to be more severe than expected for the participant’s condition.
The disease/disorde r being studied or expected progress ion, signs, or s ymptoms of 

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 71the dise ase/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscopy , appendectom y): the condition that 
leads to th e procedure is the AE.
Situations in which an untoward medic al occu rrence did not occur (social and/or 
convenience admission to a hospital).
Anticipated day -to-day fluctuations of preexisting dis ease(s) or condition(s) present 
or detected at the start of the study  that do not worsen.
Worseni ng of signs and symptoms of the malignancy  under study  should be 
recorded as AEs 
in the appropriate section of the CRF.  Disease progression 
assessed b y measur ement of malignant lesions on radiographs or other methods 
should not be reported as AEs.
10.3.2. Defini tion of SAE
If an event is not an A E per defi nition above, then it cannot be an S AE even if serious 
conditions are met (eg, hospitalization for signs/symptoms of the disease under study , death 
due to progression of disea se).
An SAE is defined as any untowa rd medical occurrence th at, at any dose:
a.Results in death
b.Is life -threatening
The term “life -threatening” in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of t he event.  I t does not refer to an e vent that 
hypothetically might have caused de ath if it were more severe.
c.Require s inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalization signifies that the participant has been detained (usually  
involving at least an overnight stay ) at the hos pital or emerg ency  ward for observation 
and/or tre atment that would not have been appropriate in the ph ysician’s office or 
outpatient setting.  Complications that occur during hospitalizati on are AEs.  If a 
complication prolo ngs hospitalization or f ulfills anyother serious criteria, the event is 
serious.  When in doubt as to whether “ hospitalization” occurred or was necessary , the AE 
should be considered serious.
Hospitalization for electiv e treatment of a preexisting conditi on that did not worsen f rom 
baseline is not c onsidered an AE.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 72d.Results in persist ent disability/incapacity
The t erm disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This d efinition is not intended to include experiences of relative ly mino r medical 
significance such as uncomplicated heada che, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle) which may  interfere with or 
prevent every day life fu nctions but do not constitute a subs tantial disruption.
e.Is a conge nital anomaly/ birth defect
f.Other situations:
Medi cal or scientific judgment shou ld be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medic al events that 
may not be immediatel y life-threatening or re sult in death or hospitalization but 
may jeopardize the p articipa ntor may  require medic al or surgical intervention to 
prevent one of the other outcomes listed in the above definition.  These even ts 
should usually be considered seri ous.
Examples of such ev ents in clude invas iveor maligna nt cance rs, intensive tre atme nt 
in anemergency  room or at home for allergic bronchospasm, blood dy scras ias or 
convulsions that do not result in hospitalization, or development of drug 
dependency  or drug abuse.
Progression of the m alignancy  unde r study  (including signs and s ymptom s of 
progression) should not be reported as an SAE unless the outcome is fatal within 
the active collection period.  Hospitalization due to signs and s ymptoms of disease 
progr ession should not be rep orted a s anSAE.  If the malignancy  has a fa tal 
outcome during the study or within the active collection period, then the event 
leading to death must be recorded as an AE on the CRF, and as an SAE with
Comm on Term inology  Criteria for Adverse Events (CTCAE) Grade 5 (s ee the 
Assessment of Intensit ysection).
Suspected transmission via a Pfizer product of an infectious agent, pathogenic or 
non-pathogenic, is considered serious.  The event may  be suspected from clinic al 
symptoms or labora tory findings indicating an infectio
n in a patient exposed to a 
Pfizer product.  The terms “suspected transmission” and “transmission” are 
considered s ynon ymous.  These cases are considered unexpected and handle d as 
serious expedited c ases by pharmacovigil ance personnel.  Such cases are also
considered for reporting as product defects, if appropriate.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 7310.3.3. Recording/Reporting and Follow -up of AEs and/or SAEs
AE and SAE Recording/R eporting
The table below summarizes the requirements for rec ording adve rse events on the CRF and 
for reporting seriou s adverse events on the Clinical Trial (CT) Serious Adverse Event 
(SAE) Report Form to Pfizer Safety .  These requirements are delineated f or 3types of 
events: (1) SAEs; (2) nonserious adverse events (AEs); and(3) exposure to the 
investigational product u nder study  during pr egnancy  or breastfeeding, and occupational 
exposure. 
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as t he AE page of the CRF.  W hen the same data are collected, the forms must be 
comple ted in a consistent manner.  AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE information.
Safety Even t Recorded on the CRF Reported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours of 
Awareness
SAE All All
Nonserious AE All None
Exposure to the 
investigational product 
under study  during 
pregnancy  or 
breastf eeding, and 
occupational 
exposur eAll AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding
Occupational exposure is 
not recorded.All (and exposure during 
pregnancy  [EDP] 
supplemental form for 
EDP)
Note: Include all SAEs 
associated wit h exposure 
during pregnancy  or
breast feed
ing. Include all 
AEs/SAEs associated with 
occu pational exposure.   
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospital progress notes, laboratory  reports, and diagnostic 
reports) related to the event.
The investigator wi ll then record all rele vant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopies of the participant’s 
medical recor ds to Pfizer Safety  in lieu of compl etion of the CT SAE Report 
Form /AE/SAE CRF page.
There may  be instances when copies of m edical records for certain cases are 
requested b y Pfizer Safety.  In this case, all participant identifiers, with the 

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 74exception of t he participant number, will be redac ted on the copies of the medica l 
recor ds before subm ission to Pfi zer Safety .
The investi gator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  Whenever poss ible, the diagnosis 
(not the individ ual signs/sy mptoms) will be doc umented as the AE/SAE .
Assessment of Intensity
The inve stigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and assign it to 1 of the following cate gories: 
GRADE Clinical Description of Severity
1 MILD adverse event
2 M ODER ATE adverse event
3 SEVERE adverse event
4 L IFE-THREATENING consequences; urgent intervention indicated
5 DEATH RELATED TO adverse event
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the defini tionof an SAE , NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess t he rela tionship betw een stud y intervention 
and each occurrence of each AE/SAE.
A “reasonable possib ility” of a relationship conveys th atthere a re facts, evidence, 
and/or arguments to sugge st a causal relationship, rather th an a relationship c annot 
be ruled out.
The investigator will use clinical judgment to determine th e relationship.
Alternative causes, such as underl ying disease(s), concomi tanttherap y, and other 
risk factors, as well as t he temporal relationship of the event to study  intervention 
administration will be considered and investigated.
The investigator wil l also consult the investigator’s br ochure (IB) and/or product 

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 75information , for marketed products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessmen t of causality .
There may  be situati ons in which an SAE has occurre d and t he investigato r has 
minimal information to include in the initial report to the sponsor.  However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial tr ansmission of the S AE data to t he spon sor.
The inves tigator may  change his/her opinion of causality  in light of follow -up 
information and send an SAE follow- up report with the updated causality  
assessment.
The causality  assessment is one of the criteria us ed when determining regulatory  
reporti ng r
equirement s.
If the investigator does not know whether or not the investigational product caused 
the event, then the event will be handled as “related to investigational product” for 
reporting purposes, as defined by the sponsor.  In addition, i f the i nvestigator 
determines that an SAE is associated w ith study  procedures, the investigator must 
record this causal relationship in the source documents and CRF, and report such 
an asse ssment in the dedicated section of t he CT SAE Report Fo rm and in 
accordanc e with the SAE reporting requirements.
Follow -upof AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluation s as medically  indicated or as reque sted by  the 
sponsor to elucidat e the n ature and/or c ausality of the AE or SAE as fully a s 
possible.  This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare professionals.
If a p articipant d ies during particip
ation i n the study or during a recognized 
follow -up period, the investigator will provide Pfizer Safet y with a cop y of any 
postmortem findings including histopathology .
New or updated infor mation will be recorded in the origi nally  comple ted CRF.
The invest igator will submit an y updated SAE data to the sponsor wi thin 24 hours 
of receipt of the information.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 7610.3.4. Reporting of SAEs
SAE Reporting to Pfizer Safety via an Electronic Data Collection Too l
The primary  mechanism for reporti ng an SAE to Pfizer Safety  will be the electronic 
data collection tool.
If the electroni c system is unavailable, then the site will use the paper SAE data 
collection tool ( see next section) in order to report the event w ithin 24 hours.
The site will enter the SAE da ta into the electroni c system as soon as t he data 
become available.
After the study  is completed at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry  of new data or c hanges to existing data.
If a site r eceives a report of a new SAE f rom a s tudy participa nt or receives updated 
data on a pre viously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form 
(seenext section) or to Pfi zer Safet y by telepho ne.
SAE R eporting t o Pfizer Safety via CT SAE Report Fo rm
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to Pfizer Safety .
In circu mstances when the facsimile is not working, notification b y telepho ne is 
acceptable with a cop y of the CT SAE Report Form se nt by  overnight mail or 
courier service.
Initial notification via telephone does not replace the need for the investigator to 
comple te and sign the CT SAE Report Form pages within the designated repo rting 
time 
frames.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 7710.4. Appendix 4: Contraceptive Guidance a nd Collection of Pregnancy Information
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participat e if they  agree to the following re quirements during 
the interventi on peri od and for at 
least 22 weeks after the last dose o f study intervention, 
which corresponds to the time needed to eliminate study  intervention(s) :
Refrain from donating sperm.
PLUS either:
Be abstinent from heterosexual intercourse with a female of ch ildbear ing potential as 
their preferred and usual lifesty le (abstinent on a long -term and persistent basis) and 
agree to remain abstinent. 
OR
Must agree to use a male condom when engaging in any  activity  that al lows for 
passage of ejaculate to another per son.
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least 1 of the following condition s applies:
Is not a WOCBP (see definiti ons below in Secti on 10.4.3).
OR
Is a WOCBP and using a contraceptive method that is h ighly  effective (with a failure 
rate of <1% per year), as described below, during the inte
rvention period and for at 
least 22weeks after the la st dose of study  intervention, which corresponds t o the time 
needed to eliminate an y study intervention(s) . The investigator should evaluate the 
effectiveness of the contraceptive method in relation ship to the first dose of study  
intervention.
The investi gato
r is respo nsible for review of medical history , menstrual history , and recent 
sexual ac tivity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy . 

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 7810.4.3. Woman of Childbear ing Potential (WOCBP)
A woman is considered fertil e following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed b efore the first dose of study  intervention, additi onal ev
aluation shoul d be 
considered.
Women in the follow ing categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Documented bilateral salpingectomy ;
Documented bilateral oophorectom y.
For individuals with pe rman ent infert ility due to an alternate medical ca use other than 
the above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion 
should be applied to determining study  entry .
Note: Documentation for any  of the above categories c an come from the site
personnel’s review of the participa nt’s medical records, medical examination , or 
medical history  interview.  The method of documentation should b e recorded in the 
participant’s medical record for the stud y.
2.Postmenopausal female:
A po stmenopausa l state is defined as age 60 years or older or no menses for 
12months without an alter native medical cause. 
A high follicle -stimulating hormone (FSH) leve l in the postmenopausal range 
may be used to confirm a postmenopausal state in women not using h ormo nal 
contra ception or hormone replacement thera py (HRT). 
Females on HRT and whose menop ausal status is in doubt will be required to 
use one of the nonestrog en hormonal highl y effective contracept ion methods 
if they  wish to continue their HRT dur ing the study.  Other wise, they  must 
discontinue HRT to a llow confirmation of postmenopausal status before study  
enrollment.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 7910.4.4. Contraception Methods
Highly Effective Met hods That Have Low User Dependency 
1.Implantable progestogen -only hormone contraception as sociate d with inhibit ion of 
ovulation.
2.Intrauterine devic e (IUD).
3.Intrauterine hormone -releasing s ystem (IUS).
4.Bilateral tubal occlusion.
5.Vasectomized partner.
Vasecto mized partner is a highl y effective con traceptive method provided that the 
partner is the sole s exua l partner of the WOCBP and the absence of sper m has 
been confirmed.  If not, an additional highl y effective method of contraception 
should be used.  The spe rmatogenesis cy cle is approximately  90days.
Highly Effective Methods that Are User Depen dent
1.Combin ed (estrog en-and progestogen -containing) horm onal contraception associated 
with inhibition of ovulation:
oral;
intravaginal;
transdermal;
injectable.
2.Proge stogen -only hormone contraception assoc iated with inhibition of ovulation:
oral;
injectab le.
3. Sex ual abstinence :
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period o f risk associated 
with the study  intervention.  The reliability  of sexual abstinence need s to be
evaluated in relation to the duration of the stud y and the preferred and usual 
lifesty le of the participant.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 80Collection of Pregnancy Information
For both unapp roved/unlicensed products and for marke ted products, an exposure during 
pregnancy (EDP) occurs if:
A female becomes, or is found to be, pregnant e ither while receiving or having been 
exposed (eg, because of treatment or environmental exposure) to the inves tigational 
product; or the female becomes or is found to be pregnant after discontinuing and/or 
being exposed to the investigational product;
An e xample of environmental exposure would be a case involving direct contact 
with a Pfizer product in a pregnant woman (eg, a nurse reports that she is pregnant 
and has been exposed to chemotherapeutic products).
A male has been exposed (eg, because of treatm ent o r environmental exposure) to the 
investigational product prior to or around the time of conception and/or is exposed 
during his partner’s pregna ncy.
If a participant or participant’s partner bec omes or is found to be pregnant during the 
participant’s treatment with the investigational product, the investigator must report this 
information to Pfizer Safety  on the CT SAE Report Form and an EDP suppl emental form, 
regardless of whether an SAE has occ urred. In addition, the investigator must submit 
informa tion regarding environmental exposure to a Pfizer product in a pregnant woman 
(eg,aparticipant reports that 
she is pregnant and has been exposed to a cytotoxic product by  
inhalation or spillage) to Pfizer Safety using the EDP supplemental form.  This mus t be done 
irrespective of whether an AE has occurred and within 24 hours of awareness of the 
exposure.  The in formation submitted should include the anticipated date of delivery  (see 
below for inform ation r elated to term ination of pregnancy ).
Follow -up is condu cted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow t he pregnancy  until 
completion (or until pregnancy  termina tion) and noti fy Pfizer Safet y of the outcome as a
follow-up to the initial EDP supplemental form.  In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason (s) for termination should be specified and, if clinicall y pos sible, the structural 
integrit y of the terminated fetus should be assessed by gross visual inspection (un less 
preprocedure test findings are con clusive for a congenital anomal y and the findings are 
reported).
If the outcome of the pregnancy  meets the criteria for an SAE (i e,ectopic pregnancy , 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live-born baby, a terminated fetus, an intrauterine fetal demi se, or a neonatal dea th]), the 
investigator should follow the procedures for reporting SAEs.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 81Additional information about pregnancy  outcomes that are reported to Pfizer Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarriage and missed abortion;
Neonat al deaths that occur within 1 month of birth shoul d be reported, without regard 
to causality , as SAEs.  In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  relate dto 
exposu
re to the investigational product. 
Additional information regarding the EDP may  be requested by  the sponsor.  Further 
follow -up of birth outcomes will be handled on a case -by-case basis (eg, f ollow -up on 
preterm infants to identify developmenta ldelay s). In the ca se of paternal exposure, the 
investi gator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his p artner.  The investigator must document in the source documents that 
the participant was gi ven the Pregnant Part ner Release of Information Form to provide to his 
partner.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 8210.5. Appendix 5: Genetics
Use/Analysis of DNA
Genetic variation may  impact a participant’s response to study  intervention, 
suscep tibility  to, and severity  and progression of disease .  Ther efore, where l ocal 
regulations and IRBs/ECs allow,
a blood sample will be collected for DNA anal ysis.
Genetic research may  consist of the analy sis of 1 or mor e candidate genes or the 
analysis of ge netic markers throughout the genome or anal ysis of the enti re genome 
(as appropriate).
The samples may  be ana lyzed as part of a multistudy  assessment of genetic factors 
involved in the response to PF-
06946860 or study interventions of this class to 
underst and treatments for the disease(s) under study  or the disease(s) themselve s.
The results of genetic analy ses m ay be reported in the clinical study  report (CSR) or 
in a separate study  summary , or may  be used for interna l decision making without 
being include d in a study report.
The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality . 
The samples will be retained as indicated:
Samples for banking (see Section 8.7.2 and8.8.1 ) will be stored indefinitely or 
other period as per local requirements. 
Participants may  withdraw their consent for the storage and/or use of their banked 
biospecimens at an y time by making a request to the investigator; in thi s case, any
remaining material will be destroy ed.  Data a lready  generated from the samples will 
be retained to protect the integrit y of existing anal yses. 
Banked biospecimens will be labe led with a code.  The key  between the code and the 
participant’s per sonally identify ing information (eg, name, address) will be held at the 
study  site and will not be p rovided to the sample bank. 

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 8310.6. Appendix 6: Liver S afety: Suggested Actions and Follow- up Assessments 
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as deter mined by  elevations in 
transaminases) are t ermed “tolerators,” while those who show transien t liver injury , but adapt 
are termed “a daptors.”  In some participants, transaminase elevations are a harbi nger of a 
more seriou s potential outcome.  These particip ants fail to adapt and therefore are 
"susce ptible" to progressive and serious liver injury , commonl y referred to as drug -induced 
liver injury  (DILI).  Participants who experience a transaminase eleva tion ab ove 3times th e 
upper limit of normal (× ULN) shou ld be monitored more frequentl y to determine if they  are 
an “adaptor” or are “susceptible.”
In the majority  of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransfera se (ALT ) precede tota l bilirubin (TBili) elevations (>2 × ULN) by  several 
days or weeks.  The increa se in TBili ty picall y occurs while AST/ALT is/are still elevated 
above 3 × ULN (i e,AST/AL T and TBili values will be elevated within the same laboratory  
sample).  In rare instan ces, by  the time TBili elevations are detected, AST/AL T values might 
have decreased.  This occurrence is still regarded as a p otential DILI.  Therefore, abnormal 
elevations in either AST OR AL T in addition to TBili that meet the criter ia outlined below 
areconsidered potential DILI (assessed per Hy ’s law criteria) cases and should alway s be 
considered important medical events, ev en before all other possible causes of liver injury  
have been excluded.
The threshold of laboratory  abnormali ties for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions.  Participants who present 
with th e following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to defini tively  dete rmine the etiology  of the abnormal laboratory  values:
Participants with AST/ALT and TBili baseline values within the normal range who 
su
bsequently  present with AST OR AL T values >3 × ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an a lkaline phosphatase value 
<2×ULN or not availabl e.
For participants with baseline AST OR ALT ORTBili values above the ULN, the 
following 
threshold values are used in the def inition mentioned above, as needed, 
depending on which values are above the ULN at b aseline:
Preexisting AST or ALT baseline value s above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased fr om 
baselinevalue b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 84Rises in AST/AL T and TBili separated by more than a few weeks should be ass essed 
individually  based on clinical judgment; any  case where uncertainty remain s asto whethe r it 
represents a potential Hy’s law case should be reviewed with the sponsor.  
The participant should return to the investig ator site and be evaluated as soon as p ossible, 
preferabl y within 48 hours from awareness of the abnormal results.  This evaluatio n should 
include laboratory  tests, d etailed history , and physical assessment.  The possibility  of hepatic 
neoplasia (primary  or secondary ) should be considered.
In addition to repeating measurements of AST and AL T and TBili for suspect ed case s of
Hy’s law, additional laboratory  tests should 
include albumin, creatine kinase (CK), direct and 
indirect bilirubin, gamma -glutam yl trans ferase (GGT), prothrombin time (PT)/int ernational 
normalized ratio (INR), total bile acids, and alkaline phos phatase .  Considerati on should also 
be given to drawing a separate tube of clotted blood and an antico agulated tube of blood for 
further testing, a s needed, for further contemporaneous a nalyses at the time of the recognized 
initial abnormalities to determine etio logy.  A detai led history , including relevant 
information, such as review of ethanol, acetamino phen (either b y itself or as a coformulated 
product in prescription or over -the-coun ter medications), recreational drug, supplement 
(herbal) use and consu mption, family histor y, sexual history , travel history, h
istory  of contact 
with a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupa tional exposure to chemicals, should be collected.  Further testing for acute
hepatitis A, B, C, D, and E infection and liver i maging (eg, biliary  tract) and collection of 
serum sample for acetaminophen drug and/or pr otein adduct levels may  be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria o f AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) case s if no 
other reason for the liver function t est (LFT) abnormalities has y et been fo
und.  Such 
potential DILI (Hy’s law) cases are to be reported as SAEs, irresp ective of avai lability 
of all the results of the i nvestigations performed to determine etiology of the LFT 
abnormalities.
A potential DILI (Hy’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been receiv ed and have excluded an alternative etiology .

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 8510.7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings That May Qualify as Adverse Event s (AEs)
Marked sinus brady cardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >280 msec.
New prolon gation of QTcF to >480 msec (absolute) or by≥60msec from baseline.
New -onset atrial flutter or fibrillation, with controlled ventricular response rate:
ie,rate <120 bpm.
New -onset ty peI second -degree (Wenckebach) atrioventricular (AV)block of 
>30seconds’ duration.
Frequent premature ventricular complexes (PVCs), triplets, or short i ntervals 
(<30 seconds) of consecutive ventricular complexes.
ECG Findings That May Qualify as Serious Adverse Events (SAEs)
QTcF prolongation >500 msec.
New ST -T changes sugg estive of my ocardial ischemia.
New -onset left bundle branch block (QRS >120 msec).
New -onset right bundle branch block (QRS >120 msec) .
Symptomatic brady cardia. 
Asystole:
In awake, s ymptom -free patients in sinus rhy thm, with documented periods of 
asystole≥3.0 seconds or any  escape rate <40 bpm, or with an escape rhy thm 
that is below the AV node; 
In awake, s ymptom -free patients with at rial fibrillation and brad ycardia with 
1 or more pauses of at least 5 seconds or longer; 
Atrial flutter or fibrillati on,with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained supraventricular tach ycardia (rate >120 bpm) (“sustained” = sho rt 
duration with relevant symptoms or lasting >1 minute).
Ventricular rh ythms >30 seconds’ duration, including idioven tricular rhy thm (rate 

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 86<40 bpm), accelerated idioventricular rh ythm (40< x <100), and 
monomorphic/poly morphic ventricular tach ycardia >100 bpm (such as torsades de 
pointes).
Type IIsecond -degree (Mobitz II) AVblock.
Complete (third- degree) heart block.
ECG Fin dings That Qualify as Serious Adverse Events
Change in pattern suggestive of new m yocardial infarction. 
Sustained ventricular tach yarrhythmias (>30 seconds’ duration).
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion.
Ventricular fibril lation/flutter.
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience.
The enumer atedlist of major events of potential clinical concern are recommended as “alerts” or 
notifications from the core ECG laboratory to the i nvestigator and Pfizer study team, and not to be 
considered as all inclusive of what to be reported as AEs/SAEs.

PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 87
CCI
PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 8810.9. Appendix 9 : Patient -Reported Outcomes Version of the Common Terminology 
Criteria for Adve rse Events PATIENT (PRO -CTCAE™)

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 8910.10. Appendix 10: Patient’s Global Impression of Severity (PGI -S)

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 9010.11. Appendix 11: Patient ’s Global Impression of Change (PGI -C)

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 9110.12. Appendix 12: PROMIS –Fatigue (version 7a)

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 9210.13. Appendix 1 3: PROMIS – Physical Function (version 8c)

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 9310.14. Appendix 14: Functional Assessment of Anorexia-Cachexia Therapy (FAACT)

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 94

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 95

PF-06946860
Protocol C3651009Final Protocol Amendment 1, 08 February 2021
PFIZER CONFIDENTIAL
Page 96 
  
 
 
 
 
 
 
 CCI
PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 9710.16. Appendix 16: ECOG Performance Status

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 9810.17. Appendix 17:RECIST 1.1 Tumor Assessment Criteria RECIST (Response 
Evaluation Criteria In Solid Tumors) version 1.1 Guidelines
Adap tedfrom E isenhauer E.A., et al.38
CATEGORIZING LESIONS AT BASELINE
Measurable Lesions
Lesions that can be accurately measured in at least one dimension.
a.Lesions with longest diameter twice the slice thicknes s and at leas t 10mm or greater 
when assessed b y CT or MRI  (slice thickness 5-8 mm).
b.Lesions with longest diameter at least 20 mm whe n assessed b y Chest X -ray. 
c.Superficial lesions with longest diameter 10 mm or greater when assessed by  caliper. 
d.Malignant lymph no des with the short axis 15 mm or greater when assessed by  CT.
NOTE: The shortest axis is used as the diameter for malignant lymph nodes, longest 
axis fo r all other measurable lesions. 
Non-measurable disease 
Non-measurable disease includes lesions too sma ll tobe considered measurable (including 
nodes with short axis between 10 and 14.9 mm) and truly  non- measurable disease suc h as 
pleural or pericardial effusions, ascites, inflammatory  breast disease, leptomeningeal disease, 
lymphangitic involveme nt of ski
n orlung, clinical lesions that cannot be accurately  measured 
with calipers, abdominal masses identified b y physical exam t hat are not measurable b y 
reproducible imaging techniques.
Bone disease: Bone disease is non-measurable with the exception of soft t issue
components that can be evaluated b y CT or MRI and meet the definition of 
measurability  at baseline.
Previous local tre atment: A previously  irradia ted lesion (or lesion subjected to other 
local treatment) is non -measurable unless it has progr essed since c ompletion of 
treatment.
Normal sites
Cystic lesions : Simple cysts should not be considered as malignant lesions and shou ld 
not be recorded either as target or non- target disease.  Cy stic lesions thought to 
represent cy stic metastases can be me asurable lesions, if they  meet the specific 
definition above.  If non -cystic lesions are also present, these are preferred as target 
lesions.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 99Normal nodes: Nodes with short axis <10 mm are considered normal and should not 
be recorded or followed either as measurabl e ornon-measurable disease.
RECORDING TUMOR ASSESSMENTS
All sites of disease must be assessed at baseline.  Baseline assess ments should be done as 
close as possible prior to study  start.  For an adequate baseline assessment, all required scans 
must be done wi thin 28 days prior to treatment and all disease must be documented 
appropriatel y.  If baseline assessment is inadequate, subsequent statuses general ly should be 
indeterminate.
Target lesions
All measurable lesions up to a maximum of 2 lesions per organ , 5 lesions in total, 
representative of all involved organs, should be identified as target lesions at baseline.  
Target les ions should be selected on t he basis of size (longest lesions) and suitability  for 
accurate repeated measurements.  Record the longe st diameter for each lesion, except in the 
case of pathological l ymph nodes for which the short axis should be recorded.  Th e sum of 
the diameters (long est for non-nodal lesions, short axis for nodal lesions) for all target lesions 
at baseline wil l be the basis for comparison to assessments performed on study . 
If two target lesions coalesce the measurement of the coalesced mas s is used.  If a 
large targe t lesion splits, the sum of the parts is used.
Measurements for target lesions that become smal l should cont inue to be recorded.  If 
a target lesion becomes too small to measure, 0 mm should be recorded if the lesion is 
consider ed to have disappeared; othe rwise a default value of 5 mm should be 
recorded.
NOTE: When nodal lesions decrease to <10 mm ( normal), the actual measurement 
should still be recorded.
Non-target disease 
All non-measurable disease is non- target.  All measurab le lesions not identified as target 
lesions are also included as non -target disease.  Measurements are not required but rat her 
asses sments will be expressed as ABSENT, INDETERMI NATE, PRESENT/NOT 
INCREASED, INCREASED.  Multiple non-target lesions in one org an may  be recorded as a 
single item on the CRF (eg, ‘multiple enlarged pelvic lymph nodes’ or ‘multiple liver 
metastases’).

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 100OBJECTIV E RE SPONSE STATUS AT EACH EVALUATION.
Disease sites must be assessed using the same technique as baseline, including consist ent 
administration of contrast and timing of scanning.  If a change needs to be made the case 
must be discussed with the ra diologist to determine if substitution is possible.  If not, 
subsequent objective statuses are indeterminate.
Target disease
Complete response: Complete disappearance of all target lesions with the exception 
of nodal disease.  All target nodes must decreas e to norm al size (short axis <10 mm).  
All target lesions must be assessed.
Partial response: Greater than or equal to 30% decrease u nder baseline of the sum of 
diameters of all target measurable lesions.  The short diameter is used in the sum for 
target nodes, whi le the longest diameter is used in the sum for all other target lesions.  
All target lesions must be assessed.
Stable: Does not qualify  for CR, PR, or progression.  All target lesions must be 
assessed.  Stable can follow PR only  in the rare case t hat the s um increases by  less 
than 20% from the nadir, but enough that a previously  documented 30% decrease no 
longer holds.
Objectiv e progression: 20% increase in the sum of diameters of target measurable 
lesions above the smallest sum observed (over base line if n
o dec rease in the sum is 
observed during therap y), with a minimum absolute increase of 5 mm.
Indeterminate: Progression has not been documented, and: 
1. One or more target measurable lesions have not been assessed ; or
2. A ssessment methods used were i nconsiste nt with those used at baseline ; or
3.One or more target lesions cannot be measured accuratel y (eg, poorly visible 
unless due to being too small to measure) ; or
4.
One or more target lesions were excised or irradiated and have not reappeared or 
increased.
Non-targetdisease
CR: Disappearance of all non- target lesions and normalization of tumor marker 
levels.  All ly mph no des must be ‘normal’ in size (<10 mm short axis).
Non-CR/Non -PD: Persistence of an y non -target lesions and/or tumor marker level 
above the norma l limits.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 101PD: Unequivocal progression of pre- existing lesions.  Generally  the overall tumor 
burden must increase suffici ently  to merit discontinuation of therapy .  In the presence 
of SD or PR in target disease, progression due to unequivocal i ncrease in non- target 
disease should be rare.
Indeterminate: Progression has not been determined and one or more non -target sites 
were not assessed or assessment methods were inconsistent with those used at 
baseline.
New Lesions 
The appearance of an y new unequivocal m alignant lesion indicates PD.  If a new lesion is 
equivocal, for example due to its small size, continued assess ment wil l clarify  the etiology .  
If repeat assessments confirm the lesion, then progression should be recorded on the date of 
the initial assessment .  A lesion identified in an area not previously scanned will be 
considered a new lesion.
Supplemental I nvestigation s
If CR determination depends on a residual lesion that decreased in size but did not 
disappear completel y, it is recommended the residu al lesion be investigated with 
biopsy  or fine needle aspirate.  If no disease is identified, objective status is CR.
If progression determination depends on a lesion with an increase possibly due to 
necrosis, the lesion may  be investigated wit h biopsy  or fine needle aspirate to clarify  
status.
Subjective progression
Patients requiring discontinuation of treatment wi thout ob jective evidence of disease 
progression should not be reported as PD on tumor assessment CRFs.  This should be 
indicated on the end of t reatment CRF as off treatment due to Global Deterioration of Health 
Status.  Every  effort should be made to document obj ective progression even after 
discontinuation of treatment.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 102Table 4. Objective Response Status at eac h Evaluation
Targ
et Lesions Non-target Disease New 
LesionsObjective 
status
CR CR No CR
CR Non-CR/Non -PD No PR
CR Indeterminate or Missing No PR
PR Non-CR/Non -PD, 
Indeterminate, or MissingNo PR
SD Non-CR/Non -PD, 
Indeterminate, or MissingNo Stable
Indeterminate or Missing Non-PD No Indeterminate
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
If the protocol allows enrollment of patients with only  non- target disease, the following 
Table 5will be used:
Table 5. Objective Response Status at each Evaluation for Patients with Non Target 
Disease Only
Non-target Disease New Les ions Objective status
CR No CR
Non-CR/Non -PD No Non-CR/Non -PD
Indeterminate No Indeterminate
Unequivocal progression Yes or No PD
Any Yes PD

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 10310.18. Appendix 18:Modification of Diet in Renal Disease Equation
GFR ( mL/min/1.73m2) = 175 x standardized S cr-1.154x age-0.203x 1.212 [if black] x 0.742 [if female] .

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 10410.19. A ppendix 19: Proposed Chronology of Procedures
Other procedures listed in the SoA may be conducted after the procedures listed below as per 
site discretion to allow for f lexibility  of participant care. For the procedures described below, 
where multiple procedures are scheduled at the same time point(s) relative to dosing, the 
below chronology  of events should be adhered to , where possible . 
Note: 
Allsample s collected are to be processed and shipped according to thelab manual.
Screening: 
Patient signature on current I RB/RC approved informed consent form MUST b e 
obtained prior to performing an y stud y -related procedures, see Section 10.1.3 .
Patient Reported Outcomes ( see Section 8.1.3 (Cohor t 1 only) .
Supine standard 12- lead ECG : obtain prior to vital signs assessment (see 
Section 8.2.3 andSection 8.2.4).
Blood samples for safety
(see Section 8.2.5) and PD (GDF - 15,Section 8.6) are to be 
collected after assessment of s upine standard 12-lead ECG and vita lsigns .  
Day 1:
Patient Reported Outcomes (
see Section 8.1.3) (Cohort 1 only ) .
Supine standard 12- lead EC G: obtain prior to vital signs assessment, and, where 
applicable, prio
rto dosing ( see Section 8.2.3 andSection 8.2.4).
Pre-dose blood samples for safe ty(see Secti
on 8.2.5), PK (seeSection 8.5), PD 
(GDF -
15, see Section 8.6), immunogenicit y (see Section 8.9), and bank ed 
biospecimens (see Section 8.7.2 a
nd Section 8.8.1) areto be collected after 
assessment of 
supine standard 12-lead ECG and vital signs.
Dosing: Administration of Investigation al Product (PF -06946860) must be given at 
least 0.5h prior to administration of SoC anti- tumor therap y.
Post-dose blood sampl es fo r PK(see Section 8.5)and PD (GDF -15, see Section 8.6)
will be collected at a minimu m of 3h post PF -
06946860 admin istration or at a
maximumby the 
end of the clinic visit . 
Week s 1 and 13:
Patient Reported Outcomes (see Section 8.1.3) (Cohort 1 only ).

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 105Blood samples for PK ( see Section 8.5), PD (GDF -15, see Section 8.6) and banked
biospecim ens (see Section 8.8.1).
Week 2
:
Patient Reported Outc omes (see Section 8.1.3) (Cohort 1 only ).
Blood samples for 
PK (see Section 8.5), PD (GDF -15, see Section 8.6) and immunoge nicity
(see Section 8.9).
Weeks 3, 6 and 9: 
Patient Reported Outcomes ( see Section 8.1.3) (Cohort 1 only ) .
Supine standard 12- lead ECG : obtain prior to vital signs assessment and, where 
applicable, prior to dosing (see Section 8.2.3 andSectio n 8.2.4).
Pre-dose blood samples for safety (see Section 8.2.5 ), PK (seeSection 8.5), PD 
(GDF -
15, See Section 8.6),immunogenicit y (see Section 8.9) and banked 
biospecimens (see Section 8.8.1) are to be collected after assessment of supine
standard 
12-lead ECG and vital signs.
Dosing : Administration of Investigational Product (PF -06946860) must be given at 
least 
0.5h prior to administration of standard of care anti-tumor the rapy.
Weeks 4, 5 and 14:
Patient Reported Outcomes (see Section 8.1.3) (Cohort 1 only ) .
Blood samples for PK ( see Section 8.5) a nd P D (GDF -15, see Section 8.6).
Week 12: 
Patient Reported Outcomes (see Section 8.1.3) (Cohort 1 only ) .
Supine standard 12- lead EC G: obtain p rior to vital signs assessment and, where 
applicable, pri or to dosing 
(see Section 8.2.3 and Section 8.2.4).
Pre-dose blood s
amples for safety (see Section 8.2.5 ), PK (see Section 8.5), PD 
(GDF -
15,See Section 8.6), immunogenicit y (see Section 8.9) and banked 
biospecimens (see Section 8.8.1 ), are to be collected after ass essm ent of supine 
standard 12- lead ECG and vi tal signs.
Dosing: Administration of Investigati onal Product (PF -06946860) must be given at 
least 0.5h prior to administra tion of standard of care anti-tumor therapy .

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 106Post-doseblood samples for PK (see Section 8.5) and P D (GDF -15, see Section 8.6), 
will be collect
ed at a minimum of 3h post PF-06946860 administration or at a 
maximu mby theendof the clinic visit . 
Weeks 15, 18 and 24: 
Patient Reported Outcomes ( see Section 8.1.3) (Cohort 1 only ) .
Supine standard 12 -lead ECG : obtain prior to vital signs assessment and, where 
applicable, prior to dosing (see Section 8.2.3 and Section 8.2.4 ).
PK(seeSection 8.5), PD (GDF - 15, see Section 8.6), immunogenicit y (see 
Section
8.9) and banked biospecimens (see Section 8.8.1) are to be collected after
assessment of 
supine standard 12- lead ECG and vital signs.
Early Termination
Patient Reported Outcomes ( see Section 8.1.3) (Cohort 1 only ) .
Supine standard 12 -lead ECG : obtain prior to vital signs assessment and, where 
applicable, prior to dosing (see Section 8.2.3 and Section 8.2.4).
Blood samples for safet y (
see Section 8.2.5), PK (seeSection 8.5), PD (GDF - 15, see 
Section 8.6), immunogenicity  (see Section 8.9) and banked biospecimens (see 
Section
8.8.1) are to be collected after assessment of supine standard 12- lead ECG 
and vital signs .

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 10710.20. Appendix 20:Alternative Measu re s During Public Emergencies
Thealternative study  measures described in this section areto be followed during public 
emergencies, including the COVID -19 pandemic. This appendix applies for theduration of 
the COVID -19 pandemic globall y and will become ef fective for other public emergencies 
only upon written notification from Pfizer. 
Use of these alternative study  measures are expected to cease upon the return of business as 
usual circumst ances(including the lifting of an y quarantines a nd travel bans/a dvisories). 
10.20.1. Eligibility
While SARS -CoV2 testing is not mandated for this study , local clinical practice standards for 
testing should be followed. A patient should be excluded if he/she has a positive 
viral test 
result for SARS -CoV 2 infection, is known to have asy mptomatic infection, or is suspected of 
having SARS -CoV2. 
10.20.2. Home Health Visits
A home health care service will
beutilized to facilitate scheduled visits per the Sc hedule of 
Activities.  Home health visits include a healthcare pro vider conducting an in -person study  
visit at the participant’s location, rather than an in -person stud y visit at the site. The 
following may  be performed during a home health visit:
The use of the home -health vi sit could be extended to include specimen c ollection for 
PK, PD and ADA during the follow -upvisits.
10.20.3. Adverse Events and Serious Adverse Events
If a participant has COVID -19 during the study , this should be reported as an adverse event 
(AE) or serious adverse events (SAE) and appropriate medical intervention provided. 
Study  treatment should continue unless the investigator/treating ph ysician is concerned about 
the safet y of the participant, in which case temporary or permanent di scontinuation may  be 
required .
If a participant is confirmed t
o have active SARS- CoV2 infection and if alteration of the 
planned anti -tumor regimen is deemed necessary , the study  medical monitor should be 
consult edregarding how to manage the study  treatme nt, including potential temporary  or 
permanent discontinuati
onof the study  treatment.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 10810.21. Appendix 21:Abbreviations
The following is a list of abbreviations that may  be used in the protocol. 
Abbreviation Term
Abs Absolute
ACS anorexia and cachexia subsca le
ADA antidrug antibodies
ADCC antibody  dependent cell -mediated cytotoxicity
AE adverse event
AIDS Acquired Immunodeficiency  Syndrome
AJCC American Joint Committee on Cancer
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC168H area unde rthe curve from the time of dose administration up to 
168 hours
AUC inf area under the serum c oncentration time profile from time zero 
extrapolated to infinite time
AUC last area under the serum concentration time profile from time zero to 
the time o f thelast quantifiable concen tration 
AUC tau area under the serum concentration -time curve over the dosing 
interval tau
AV atrioventricular
BBS Biospecimen Banking S ystem
-hCG beta human chorionic gonadotropin
BLQ Below the limit of quantification
BMI body mass index
BP blood pressure
BUN blood urea nitro gen
Cav average concentration
CDC comp lement dependent cy totoxicity
CFR Code of Federal Regulations
CHF Congestive heart failure
CIOMS Council for International Organizations of Medical Scien ces
CK creatine kinase
CKD chronic kidney  disease
CL/F apparent clearance of drug from eg, plasma
Cmax maximum observed concentration
CO 2 carbon dioxide (bicarbonate)
COPD Chronic o bstructive pulmonary  disease
CONSORT Consolidated Standards of Repor tingTrials
CRF case report f orm
CRO contract research org anization
CRP C-reactive protein

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 109Abbreviation Term
CRU clinical research unit
CSR clinical study  report
CT clinical trial
CT scan Computed tomograph y scan
CTCAE Common Terminology  Criteria for Adverse Events
DILI drug-induced liver injur y
DMC data monitoring committ ee
DNA deox yribonucleic acid
DU dispen sable unit
EC ethics committee
ECG electrocardiogram
ECL electrochemiluminescent
ECOG Eastern Cooperative Oncology  Group 
eCRF electronic CRF
EDP expo sure during preg nancy
EMA European Medicines Agency
Emax maximal effect
EOT End of Treatment
ePRO electronic Patient Reported Outcome
ET Early Termination
EU European Union
EudraCT European Clinical Trials Database
FAACT Functional A ssessment of A norexia-Cachexia Therap y
FACT -G Functional Assessment o f Cancer Therap y -General
Fc fragment cry stallizable gamma 
FDA Food and Drug Administration
FIH first in human
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GDF -15 growth differ entiation factor 15
GDNF glial cell -derived neurotrophi c factor
GFR Glomerular Filtration Rate
GFRAL glial cell -derived neurotrophic factor (GDNF) family receptor 
alpha -like
GGT gamma -glutamy l transferase
GI gastrointestinal
HBV hepati tis B virus
HCV hepatitis C v irus
HIPAA Health Insurance Portability and Accountability  Act
HIV human immunodeficiency virus
HRT hormone replacement therap y
HRQoL Health Related Quality  of L ife

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 110Abbreviation Term
IB investigator’s brochure
ICD informed consent documen t
ICH Interna tional Council f orHarmonisation
ID identification
IgG1 immunoglobulin gamma -1 
IgG1κ immunoglobulin gamma -1 with kappa light chains
IND investigational new drug 
INR international normalized ratio
IP investigational product
IP manual investigational product manual
IRB institutional review board
IRT interactive response technolo gy
IUD intrauterine device
IUO Investigational Use Onl y
IUS Intrauterine hormone -releasing s ystem
IV intravenous
IWR interactive Web -based response
LBBB left bundle branch block
LFT liver function test
LSMI Lumbar Skeleta l Muscle Index
LSLV last s ubject last visit 
mAb monoclonal antibody
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MDRD modification of diet in renal d isease
MIC-1 Macrophage Inhibitory  Cytokine 1
MRI magnetic reso nance imaging
MSD Meso Scale Discovery
MSI-H metastatic microsatellite instability -high
N/A not applicable
NAb neutralizing antibodies
NCI National Cancer Institute
NIMP noninvestigatio nal medicinal product
NOAEL no-observ ed-adverse -effect level
NRS numerical rating scale
NSCL C non-small cell lung cancer
NOAEL no-observed -adverse -effect level
NYHA New York Heart Association
PCD primary  completion dat e
PD pharmacod ynamic(s)
PGI-C Patient Global I mpression of Change

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 111Abbreviation Term
PGI-S Patient Global I mpress ion of Severit y
pH potential of hy drogen
PI principal investigator
PK pharmacokinetic(s)
PR pulse rate
PRO -CTCAE Patient- Reported Outcomes Version of the Common Terminology  
Criteria for Adverse Events
PROMI S Patient -Reporte d Outcomes Measurement Info rmation Sy stem
PT prothrombin time
PVCs premature ventricular complexes
Q1W administered every  week
Q2W administered every  2 weeks
Q3W administered every  3 weeks
QTc corrected QT
QTcF corrected QT (Fridericia method)
qual qualitative
RBC red blood cell
RECI ST Response Evaluation Criteria in Solid Tumors
RET rearranged during transfection
RNA ribonucleic acid
SAE serious adverse event
SAP statistica l analy sis plan
SC subcutaneous
SD standard deviation
SMP study  mon itoring plan
SoA schedule of activities
SoC standard of care
SOP standard operating procedure
SRSD single reference safet y document
SToD study  team on demand
SUSAR suspected unexpe cted serious adverse reaction
t½ terminal elimination half -life
TBili total bilirubin
TEAE treatment emergent advers e event
TGF transforming growth factor beta
Tmax time for C max
TMDD target -mediated drug disposition
ULN upper limit of normal
US United States
WBC white blood ce ll
WOCBP woman of childbearing potent ial

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 11211.REFERENCES
1. Tsai, VW, Husaini, Y., M anandha r, R., etal. Anorexia/cachexia of chronic diseases: a 
role for the TGF -β family  cytokine M IC-1/GDF15. Journal of cachexia, sarcopenia and 
muscle 2012; 3(4): 239 -243.
2. Petry  CJ, Ong KK, Burling KA, et al. GDF15 concentrations in maternal serum 
associated with vomiting in pregnancy : the Cambridge baby  growth study . BioRXIV. 
2017; 1:221267.
3. Ponnaluri, V.K., Vadlapatla, R., Vavilala, D., et al., Hy poxia induced expression of 
histone ly sine demeth ylases: implications in oxy gen-dependent retinal neovascular 
diseases. Biochem B iophy s Res Commun, 2011. 415(2): 373 -7.
4. Krieg, A.J., Rankin, E.B., Chan, D ., et al., Regulation of the histone demethy lase 
JMJD1A by  hypoxia -inducible factor 1 alpha enhances hy poxic gene expression and 
tumor growth. Mol Cell Biol, 2010. 30(1): 344
-53.
5. Albertoni, M., Shaw, P.H., Nozaki, M., et al., Anoxia induces m acrophage inhibitory  
cytokine -1 (MIC -1) in glioblastoma cells independently  of p53 and HIF -1. Oncogene, 
2002. 21(27): 4212 -9.
6. Akiy ama, M., Okano, K., Fukada, Y., Okano, T., Macrophage inhibitory  cytokine MIC -
1 is upregulated b y short -wavelength light in cultured normal human dermal fibroblasts. 
FEBS Lett, 2009. 583(5): 933-7.
7. Bottner, M., Suter -Crazzolara,C, Schober, A., Unsicker, K. , Expression of a novel 
member of the TGF -beta superfamil y, growth /differentiation factor-15/macrophage-
inhibiting cy tokine -1 (GDF -15/MIC- 1) in adult rat tissues. Cell Tissue Res, 1999. 
297(1): 103-10.
8. Wang, X., Li, Y., Tian, H., et al., Macrophage inhibitory  cytokine 1 (M IC-1/GDF15) as 
a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma. BMC Cancer, 
2014. 14: 578.
9. Welsh, J.B., Sapinoso, L .M., Kern, S.G., et al., Large -scale delineation of secreted 
protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S 
A, 2003. 100(6): 3410 -5.
10. Breit, S.N., 
Carrero, J.J., Wang -Wei Tsai, V., et al., Mac rophage inhibitory  cytokine - 1 
(MIC-1/GDF15) and mortality  in end-stage renal disease. Nephrol Dial Transplant, 
2012. 27(1): 70-5.
11. Patel, M.S., Lee, J., Baz, M., et al., Growth differentiation fac tor-15 is associated with 
muscle mass in chronic obstructive pulmonary  disease and promotes muscle wasting in 
vivo. J Cachexia Sarcopenia Muscle, 2016. 7(4): 436-48.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 11312. Lu, Z.H., Yang, L., Yu, J.W., et al., Weight loss correlates with macrophage inhibitory 
cytokine -1 expression and might influence outcome in patients w ith advanced 
esophageal squamous cell carcinoma. Asian Pac J Cancer Prev, 2014. 15(15): 6047 -52.
13. Lerner, L., Hayes, T.G., Tao, N., et al., Plasma growth differentiation factor 15 is 
associated wit hweight loss and mortality  in cancer patients. J Cachexia Sa rcopenia 
Muscle, 2015. 6(4): 317-24.
14. Lerner, L., Tao, J., L iu,Q., et al., MAP3K11/GDF15 axis is a critical driver of cancer 
cachexia. J Cachexia Sarcopenia Muscle, 2016. 7(4): 467-82.
15.
Lerner L, Gyuris J, Nicoletti R, et a l. Growth differentiation factor - 15(GDF -15): A 
potential biomarker and therapeutic target for cancer- associated weight loss. Oncol Lett. 
2016; 12(5): 4219 -23.
16. Gyuris, J. and L . Lerner, Patent WO/2015/196142 Treatment of congestive heart failure 
and other cardiac d ysfunction using a gdf15 m odulator 2015: United States.
17. Kempf, Tibor, von Haehling, S., Peter, T., et al. Prognostic utility  of growth 
differentiation factor -15 in patients with chronic heart failure. Journal of the Americ an 
College of Cardiology  2007; 50(11): 1054-1060.
18. Brown, D.A ., Ward, R.L., Buckhautts, et al., MI C -1 serum level and genotype: 
associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res, 
2003. 9(7): 2642-50.
19. Brown, D.A., Lindmark, F ., Stattin, P., et al., Macrophage inhibitory  cytokine 1: a n ew 
prognostic marker in prostate cancer. Clin Cancer Res, 2009. 15(21): 6658 -
64.
20. Blanco -Calvo, M., Tarrio, N., Reboredo, M., et al., Circulating levels of GDF15, MMP7 
and miR- 200c as a poor prognostic signature in gastric cancer. Future Oncol, 2014. 
10(7): 1187-202.
21. Anand, I.S., 
Kempf, T., Rector, T. S., et al., Serial measurement of growth -
differentiation factor -15 in heart failure: relation to disease severity  and prognosis in the 
Valsartan Hear t Failure Trial. Circulation, 2010. 122(14): 1387-95.
22. Rohatgi , A., Patel, P., Das, S.R., et al., Association of growth differentiation factor -15 
with coronary  atherosclerosis and mortality  in a young, multiethnic population: 
observations from the Dallas He art Study . Clin Chem, 2012. 58(1): 172 -82.
23. Nair, V., Robinson -Cohen, C., Smith, M.R., et al., Growth Differentiation Factor -15 and 
Risk of CKD Progression. J Am Soc Nephrol, 2017. 28(7): 2233-2240.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 11424. Martinez, C.H., Freeman, C.M., Nelson, J.D., et al., GDF -15plasma levels in chronic 
obstructive pulmonary  disease are associated with subclinical coronary  artery  disease. 
Respir Res, 2017. 18(1): 42.
25. Johnen, H., Lin, S., Kuffner, T., et al., Tumor -induced anorexia and weight loss are 
mediated b y the TGF -beta supe rfamily  cytokine MI C-1. Nat Med, 2007. 13(11): 
1333-40.
26. Mullican, S.E., Lin-Schmidt, X., Chin, CN., et al., GFRAL is the receptor for GDF15 
and the ligand promotes weight loss in mice and nonhuman primates. Nat Med, 2017. 
23(10): 1150-1157.
27. Emmerson, P.J. ,Wang, F., Du, Y., et al., The metabolic effects of GDF15 are mediated 
by the orphan receptor GFRAL. Nat Med, 2017. 23(10): 1215 -1219.
28. Yang, L., Chang, CC, Sun, Z., et al., GFRAL is the receptor for GDF15 and is required 
for the anti -obesit y effects of th eligand. Nat Med, 2017. 23(10): 1158 -1166.
29. Hsu JY, Crawley  S, Chen M, et al. Non -homeost atic body  weight regulation through a
brainstem -restricted receptor for GDF15. Nature 2017; 550(7675): 255-9.
30. Dew ys, W. D., et al., Prognostic effe ct of weight loss pr ior to chemotherapy in cancer 
patients. The American Journal of Medicine, 1980. 69(4): 49 1-497.
31. Li, C , Wang X, C asal I, et al. Growth differentiation factor 15 is a promising diagnostic 
and prognostic biomarker in colorectal cancer. J
CellMol M ed. 2016; 20(8) : 1420 - 6.
32. Jakubowska , K, Pry czynicz A, Dy micka - Piekarska V, et al. The growth differentiation 
factor -15 (GDF -15) can be useful in the detection of distant metastases in sera of 
colorectal cancer patients. Prog Health Sci . 2016; 6(1) : 40- 8.
33. Bachmann, J , Heiligensetzer M, Krakowski -Roosen H, et al. Cachexia worsens 
prognosis in patients with resectable pancreatic cancer. JGastrointest Surg . 2008;12(7) : 
1193-201.
34. Elecs ys®GDF -15 package insert (2017). Documentation Roche Diagnostics, Bâle.
35. Altena , R., Rudol fSN F ehrmann, Boer, H., et al . Growth differentiation factor 
15(GDF -15) plasma levels increase during bleomy cin
-and cisplatin -based treatment of 
testicular cancer patients and relate to endothelial damage. PLoS One 10, no. 1 (2015): 
e0115372.
36. Fearon K, S trasser F, Anker SD, et al. Definition and classification of cancer cachexia: 
an internationa l consensus. L ancet On col2011;12(5): 489-95.

PF-06946860
Protocol C3651009
Final Protocol Amendment 1,08 February 2021
PFIZER CONFIDEN TIAL
Page 11537. Levey  AS, Coresh, J, Greene, T, et al.  Using Standardized Serum Creatinine Values in 
the Modification of Diet in Rena lDisease Study  Equation for Estimating Glomerular 
Filtration Rate. Ann Intern Med. 2006;145: 247-254.
38. Eisenhauer EA, Therasse P, B ogaerts J, et al. New response evaluation criteria in solid 
tumours: revised RECI ST guideline (version 1.1). Eur J of Cancer 2 009; 45(2): 228-47.
39. Rochette L, Zeller M, Cottin Y, et al. Insights in to mechanism s of GD15 and receptor 
GFRAL: Therapeutic targets. Trends Endocrinol Metab. 2020 Dec;31(12):939 -
951.
